Medical Research Council (MRC) grading of muscle strength.
\r\n\t
\r\n\t-production; advances in decline curve analysis, determining of optimal well spacing, parent-child wells relation, frat hit, stress shadowing, well interference,
\r\n\t-completion; determining optimal fracture spacing, optimal pad volume, optimal proppant volume, size and type, fiber optics,
\r\n\t-environmental aspects; produced water management, environmentally sustainable operation, footprint, and water consumption,
\r\n\t-improved oil recovery; Huff and Puff gas injection, surfactant injection, pilot tests, upscaling of lab-results to pilot-scale and field-scale,
\r\n\t-economics; integration of gas utilization, reducing operational costs, and water treatment.
Probiotic as a term is a relatively new word meaning “for life” and it is currently used to describe a group of bacteria when administered in sufficient quantity, confer beneficial effects for humans and animals [1]. The concept of probiotic bacteria is very old, and is associated with the consumption of fermented foods by human beings, for thousands of years. Since ancient times, man has made and eaten probiotic foods. The earliest types of probiotic food were cheeses and milks made by lactic acid bacterial (LAB) and fungal fermentation, and leavened bread fermented by yeasts fermentation [2]. Fermented food’s health benefit has also been long known. Hippocrates and other scientists in the early ages had observed that some disorders of the digestive system could be cured by fermented milk, also, Plinius, the Roman historian, stated that fermented milk products can be used for treating gastroenteritis [3].
In the modern ages, the concern to understand the importance and mechanisms of action of probiotic bacteria to exert their beneficial effects has been raised. In the early 1900s, the Russian microbiologist Ilya Mechinikov, Nobel Prize laureate, attributed the good health and longevity of Bulgarian peoples to their high consumption of fermented probiotic foods. He not only identified the health-giving bacteria used to ferment these foods, he also concluded that the general human being’s health is function of the balance between beneficial "good" probiotic bacteria and disease-causing “bad” bacteria in human gut [4]. At this time Henry Tissier, a French pediatrician, observed that children with diarrhea had in their stools a low number of bacteria characterized by a peculiar, Y shaped morphology, and these “bifid” bacteria were abundant in healthy children. Also, Tissier found that these bifidobacteria are dominant in the gut flora of breast-fed babies. The isolated bacterium named Bacillus bifidus, and was later renamed to the genus Bifidobacterium. Accordingly, he suggested that these bacteria could be administered to patients with diarrhea to help restore a healthy gut flora [2,3]. This claimed effect was due to bifidobacteria displacement of proteolytic bacteria causing the disease. The works of Metchnikoff and Tissier were the first scientific suggestions about the probiotic use of bacteria. However, In 1917, during sever shigellosis outbreak, the German professor Alfred Nissle isolated a nonpathogenic strain of Escherichia coli from the feces of a soldier who did not develop enterocolitis. Disorders of the intestinal tract were frequently treated with viable nonpathogenic bacteria to change or replace the intestinal microbiota. The E. coli strain Nissle 1917 is one of the few examples of a non-LAB probiotic. It was till 1960s, when the word "probiotic" was first proposed to describe substances produced by microorganisms and promote the growth of other microorganisms [5]. In 1989, Fuller, in order to point out the microbial nature of probiotics, redefined the word as "A live microbial feed supplement which beneficially affects the host animal by improving its intestinal balance" [6,7]. Another definition was proposed by [6] "a viable mono or mixed culture of bacteria which, when applied to animal or man, beneficially affects the host by improving the properties of the indigenous flora". A more recent, but probably not the last definition is "live microorganisms, which when consumed in adequate amounts, confer a health effects on the host beyond inherent basic nutrition [1,7].
As investigations continued in the probiotic field, its concept has been expanded to include bacteria from intestinal origin beside those bacteria isolated from fermented dairy products [8]. Nowadays, probiotic bacteria are available in a variety of food products, dietary supplements [9] and drugs [10]. Food products containing are almost dairy products – fluid milk and yogurt – due to the historical association of LAB with fermented milk. The most frequently used bacteria in these products include the Lactobacillus and Bifidobacterium species. Recently, new types of food products containing probiotic bacteria started to be introduced into the markets, including nondairy products, such as chocolate, cereals, beverages, fruits and vegetables products. In the near future wide range of nontraditional food products containing probiotic bacteria are expected to be introduced into the markets, as the researches in probiotic products development continue in both scientific and commercial centers around the world.
Safety considerations of probiotic bacteria are of high importance, as most probiotic bacteria are marketed in foodstuffs or feed supplements. The safety of these microbes has been confirmed through a long experience of safe use in food as starter cultures [11-13]. Bacteria such as Lactobacillus, Leuconostoc, and Pediococcus species have long been involved in food processing throughout human history, and the ingestion of foods containing live dead bacteria, and metabolites of these bacteria has taken place for many centuries [14]. Generally, LAB are classified as generally recognized as safe (GRAS), and there were no reports of any harmful effects from the consumption of these bacteria through the long history of their use in the processing of many foods (i.e. fermented dairy, fermented vegetables …etc.) [15]. In an epidemiological study of lactobacilli bacteremia case reports, [16] concluded that the increased usage of probiotic products of lactobacilli did not cause any increase in incidence or frequency of bacteremia in Finland. However, it was found that under certain conditions, some lactobacilli strains have been associated with adverse effects, such as rare cases of bacteremia [12]. Ecologically, bifidobacteria are the predominant bacteria in the intestinal tract of breast-fed infants and are believed to contribute to the good health of infants. Until now, the safety of the bifidobacteria has not been questioned, as the reports of a harmful effect of these microbes on the host are very rare.
The concern of probiotic bacteria safety has been raised with the more recent use of intestinal isolates of bacteria delivered in high numbers to severely ill patients. Use of probiotic bacteria in ill persons is restricted to the strains and indications with proven efficacy. A multidisciplinary approach is necessary to assess the toxicological, immunological, gastroenterological, pathological, infectivity, the intrinsic properties of the microbes, virulence factors comprising metabolic activity, and microbiological effects of probiotic strains [1,17]. Conventional toxicology and safety evaluation is not sufficient, since a probiotic is meant to survive and/or grow in human colon in order to benefit humans. Several methods have been developed for evaluation the safety of LAB through the use of in vitro studies, animal studies, and human clinical studies [14]. Also, proposed studies on intrinsic properties and interactions between the host and probiotic bacteria can be used as means to assess the safety of probiotic bacteria [17,18]. Evaluation of the acute, sub-acute and chronic toxicity of ingestion of extremely large quantities of probiotic bacteria should be carried out for all potential strains. Such assessment may not be necessary for strains with established documented use.
Thus, safety considerations of probiotic bacteria should include:
Antibiotic resistance profiles.
Infectivity in immune-compromised animal models
Toxin production: probiotic bacteria must be tested for toxin production. One possible scheme for testing toxin production has been recommended by the EU Scientific Committee on Animal Nutrition.
Hemolytic activity.
Metabolic activities (D-lactate, bile salt de-conjugation).
Genetic and pathological side effects.
Epidemiological surveillance of adverse incidents in consumers (post market).
Most bacteria, including LAB and probiotic bacteria are resistant to some antibiotics. This resistance may be related to chromosomal, transposon or plasmid located genes [19]. However, data available on situations in which these genetic elements could be transferred is not sufficient, and whether the situation could arise to become a clinical problem is unknown yet. There is a concern over the use of probiotic bacteria that contain specific drug resistance genes in foods. Probiotic bacteria contain transferable drug resistance genes should not be used for human. So, there is an urgent need for the development of standardized methodology for the assessment of drug resistance profiles in lactobacilli and bifidobacteria. Due to the relevance of this problem, it has been suggested that further research is needed to assess the antibiotic resistance of these bacteria. When dealing with the selection of probiotic strains, it is recommended that probiotic bacteria should not harbor transferable genes encoding resistance to clinically used drugs. Also, research is needed concerning the antibiotic resistance of lactobacilli and bifidobacteria and the potential for transferring genetic elements to other intestinal and/or food borne bacteria. For example, some strains of Enterococcus display probiotic properties, but it was found that Enterococcus is emerging as an important cause of nosocomial infections and isolates are increasingly vancomycin resistant. Accordingly, Enterococcus is not recommended as a probiotic for human use [14].
As the global probiotic markets are expanding rapidly, the harmonization of national and international regulations and guidelines are becoming extremely important for evaluating the efficacy and safety of probiotic bacteria. Hence, there would always be a possibility of spurious and ineffective probiotic products with false claims being marketed, it becomes important that these products are standardized and fulfill essential prerequisite before being marketed. So far, there is no international harmonization of probiotic product regulations. Depending on the intended use of a probiotic, whether as a food/food ingredient, a dietary supplement, and/or a drug, regulatory requirements differ greatly among different countries [20]. For most countries, if a probiotic is to be used as a drug, then it must undergo the regulatory process as a drug, which is similar to that of any new therapeutic agent. The probiotic drug safety and efficacy for its intended use must be evaluated and approved before marketing. But, if a probiotic is to be used as a dietary supplement, it is considered as foods, and then these products do not need any evaluation or approval before being marketed. However, there is an urgent need for harmonization of these regulatory standards on probiotic bacteria at the international level to ensure the safety and efficacy of probiotic products for their effective utilization in different countries around the world. However, for most countries, probiotic bacteria are regulated under food and dietary supplements because most are taken orally as foods. These are differentiated from drugs in a number of ways, especially with respect to claims. Drug claims include efficacy in the treatment, mitigation or cure of a disease, whereas foods, feed additives and dietary supplements can only make general health claims, such as structure/function claim [21,22]. A ‘health claim’ is defined as “a statement, which characterizes the effect relationship of any substance to a disease or health-related condition, and these should be based upon well-established scientific evidences from national or international public health bodies. Examples include ‘protects against cancer’. A structure/function claim is defined as “a statement of nutritional support that affects the structure or functioning of the human body, or characterizes the mechanism to maintain such structure or function. For example ‘supports the immune system’ [23,24]. No therapeutic claim or disease-prevention is known to have been approved by the United States, EU, or Canada [23].
The Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotic bacteria has developed and proposed guidelines for evaluating probiotic bacteria in food that could lead to the harmonization of regulations and standards of probiotic bacteria health claims [1,25]. The recommended guidelines included: 1) using a combination of phenotypic and genotypic tests to identify the genus and species of the probiotic strain, as clinical evidences suggested that the health benefits of probiotic bacteria may be strain specific, 2) in vitro testing to delineate the mechanism of the probiotic effect, and 3) substantiation of the clinical health benefit of probiotic agents with human trials. In addition, the manufacturer should take on the responsibility (albeit not required by law) of providing guidance to consumers or clinicians about the type and extent of safety assessments that have been conducted on its products. According to The Joint FAO/WHO Expert Consultation recommendations, even though, that in most countries, only general health claims are allowed on probiotic foods, it is recommended that specific health claims may be allowed on probiotic foods, where sufficient scientific evidence is available. Such specific health claims should be permitted on the label and promotional material.
In the USA, depending on how probiotic bacteria are intended to be used, they may be regulated as a dietary supplement and/or a biological agent. Biological agents require pre-market evaluation of the safety, purity and potency, as well as efficacy for approval by FDA, whereas, dietary supplements do not [25]. According to FDA, the determining factor as to whether a probiotic is a dietary supplement is whether it has been used as a food. A probiotic used for diagnosis, cure, mitigate, treat, or prevent disease is considered as a drug and/or a biological product. FDA’s Center for Biologics Evaluation and Research (CBER) regulates probiotic products when used for clinical indications. CBER’s Office of Vaccines Research and Review has regulatory jurisdiction over most probiotic products for clinical use [26]. Nevertheless, most probiotic bacteria are regulated as dietary supplements, which were regulated in 1994 by FDA via the Dietary Supplement and Health Education Act (DSHEA). According to DSHEA, probiotic dietary supplements may have a structure/function claim. It is the manufacturer responsibility to notify the FDA before marketing any probiotic product, and determine that the dietary supplements that it manufactures or distributes are safe, and that any claims made about them are substantiated by adequate evidence to show that they are not false or misleading. The manufacturer must also state on the label that the dietary supplement product is not intended to ‘diagnose, treat, cure or prevent any disease’ because only a drug can legally make such a claim. Unlike Canada and some European countries, the United States has no governmental standards for probiotics. As most probiotic bacteria are claimed to be GRAS, they are not subjected to any specific standards [22]. Currently there are no functional foods are regulated or marketed in the USA, and this is partly because there is no internationally accepted definition of a functional food [24]. The International Food information Council has suggested that functional foods be defined as foods that provide health benefits beyond basic nutrition [24,25].
As in the international level, the different European countries have different national regulations for probiotics. For example in Germany, France, and Italy, the probiotic bacteria in capsule, tablet or powder form have the pharmaceutical products status, whereas, in Denmark, Finland Netherlands, and Sweden, same probiotic products are regulated as food and/or food supplements [24,28]. Food supplements do not require authorities’ notification or registration before marketing. In the EU, probiotic bacteria are legally regulated either as 1) foods; for examples, yogurts, dairy drinks, fermented fish, meats & vegetables, and cheeses; 2) food supplements; for examples, tablets, pills, powders, capsules, liquid concentrates in vials, and soft gels; or 3) novel foods. Novel foods are defined as foods/food a ingredient that does not have a significant history of human consumption within the EU countries prior to 15th May 1997 (97/258/EC). According to the novel food regulations, if a probiotic does not have a history of safe use, safety and quality guidelines are laid down. To date, probiotic bacteria for human foods are not governed under specific EU regulatory frame works. Novel Food regulation EU 258/97 is to relevant probiotic in some specific cases. There is therefore a considerable need for harmonization of European legislation on probiotic bacteria considered as food supplements. In contrast with the situation in the USA, even though, that the level of awareness and acceptance of probiotic bacteria in Europe is advanced, neither a legal definition nor specific regulations governing functional foods exist. However, according to Food Supplements Directive 2002/46/EC ‘‘food supplements’ are defined as” foodstuffs the purpose of which is to supplement the normal diet and which are concentrated sources of nutrients or other substances with a nutritional or physiological effect, alone or in combination, marketed in dose form, namely forms such as capsules, pastilles, tablets, pills and other similar forms, sachets of powder, ampoules of liquids, drop dispensing bottles, and other similar forms of liquids and powders designed to be taken in measured small unit quantities”. Even though, that this directive has generally been elaborated for vitamins and minerals, also, it already states that specific regulations must be laid down for nutrients other than vitamins and minerals. Given that probiotic bacteria fall within this definition of food supplements as used in this Directive, regulation of this kind can help to guarantee the safety and quality of the probiotic products [24].
Japan is the only country that have legally defined and regulated functional foods, including probiotics, under the “Foods for Specific Health Use” (FOSHU) system by the Japanese Ministry of Health and Welfare [27]. The FOSHU system allows several health claims for probiotic bacteria include: 1) colonizes the intestines alive, 2) Increases the intestinal beneficial bacteria, 3) Inhibits harmful bacteria, 4) Maintains the balance of the intestinal flora, 5) Maintains the intestines good health, and 6) Promotes the maintenance of a good intestinal environment [28]. As a result, several probiotic products had received FOSHU approval in Japan [27]. FOSHU system requires the approval of the specific health claim prior to use, and this approval should be based on documented scientific evidences. FOSHU approved products are labeled for the specific health claim. In addition to approved FOSHU foods, many unapproved functional foods are available in Japan. These unapproved foods cannot carry an associated health claim but rely instead on consumer awareness of the probable health benefits of the ingredients [28].
Health Canada (HC) and Natural Health Product Directorate (NHPD) which became a law in 2004 are the responsible regulators for food label and health claims in Canada [24,30]. Natural Health Products (NHPs) are considered as a subset of drugs under the Food and Drugs Act, and require assessment and licensing before being marketed. NHPs must be substantiated by sufficient evidence of safety and efficacy under recommended conditions of use, and must be manufactured under Good Manufacturing Practices. For HC/ NHDP, a probiotic is limited to nonpathogenic microorganisms, and is defined “as mono or mixed culture of live micro-organisms that benefit the microbiota indigenous to humans”. Foods such as yogurt that contain ‘‘microbes’’ are controlled by the Food Products Directorate of HC. As with other food products regulated by HC, probiotic bacteria can carry a structure/function claim, a risk reduction claim, or a treatment claim. The amount and quality of the data to be supplied depend on the claim that is sought. The HC/NHPD regulations concerning probiotic bacteria have requirements related to toxicity and safety [23,31]. It is suggested to use a multidisciplinary approach to assess the pathological, genetic, toxicological, immunological, gastroenterological, and microbiological safety aspects of probiotic strains. Probiotic products in either capsule or liquid form as nutraceuticals’ or as functional foods can be found in the marketplace in Canada today. It is not known how many petitions HC has received from companies related to probiotics. However, since its inception in 2004, HC/NHPD has not issued an approved health claim for any probiotic product [30].
Appropriate labeling and health claims are a pre-requisite for the consumer to make an informed choice. In addition to the general labeling requirements under the food laws of each country, necessary information should also be stated on the label [23,39]. Even though, that currently in most countries, only general health claims are labeled on foods containing probiotics, it is also recommended that specific health claims be allowed relating to the use of probiotics, where sufficient scientific evidence is available [22,25]. For example, the claim that a probiotic ‘reduces the incidence and severity of rotavirus diarrhea in infants’ would be more informative to the consumer than a general claim that probiotic bacteria’ improve gut health’. Such specific health claims should be permitted on the label and promotional material. Also, it is the responsibility of the product manufacturer that an independent third party review by scientific experts in the field be conducted to establish that health claims are truthfully and not misleading labeled [20].
Hence, the following information must be displayed on the label:
Genus, species and strain: To clarify the identity of a probiotic present in food the microbial species must be stated on the label. Genus, species and strain designation should follow the standard international nomenclature. If the selection process has been undertaken, the identity of the strain should also be included since all probiotic effects are strain specific. Strain designation should not mislead consumers about the functionality of the strain.
Minimum viable numbers of each probiotic strain at the end of shelf life: The number of probiotic bacteria in food products should be clearly enumerated in order to include them on the label. The label should state the viable concentration of each probiotic present at the end of shelf life. The minimum efficacy level for each probiotic strain that to be maintained till the end of shelf life of product should be scientifically proven.
The serving size that delivers the effective dose of probiotic bacteria related to the health claim.
An accurate description of the physiological effect, as far as is allowable by law with the required scientific evidence.
Proper storage conditions including the temperature at which the product should be stored.
Corporate contact details for consumer information.
Safety in the conditions of recommended use.
Label information must not mislead the consumers to understand that consumption of the food, ingredient or nutrient of such food, can treat, relieve, cure or prevent a disease.
Dairy foods, fermented and non-fermented, have played important roles in the diet of humans worldwide for thousands of years. Since the observations of Mechinikov, in the early 1900s, there has been an increasing interest in the benefits of certain microorganisms; i.e. LAB and probiotic gut flora, and their effect on human general health, body functions, and life longevity. Currently hundreds of probiotic dairy products are manufactured and consumed around the world; typical examples include pasteurized milk, ice-cream, fermented milks, cheeses and baby milk powder [31-35]. The overall pattern of consumption of all types of probiotic dairy products is steadily expanding in the majority of countries in the world. The beneficial health claims are the main reasons behind the popularity and high consuming rates of these products in different communities. Milk is an excellent medium to carry or generate live and active cultured dairy products. The buffering capacity of milk helps to improve the survival of probiotic flora in the GI tract [35]. However, fermented foods remain the main vehicle to deliver probiotic bacteria [9,36]. Among the fermented milk products, yoghurt is by far the most popular and important vehicle for the delivery of probiotic bacteria [32,37]. Fermented dairy foods are well suited to promoting the positive health image of probiotic bacteria for several reasons: 1) fermented dairy foods already have a positive health image; 2) consumers have the fact that fermented foods contain living microorganisms (starter cultures); and 3) probiotic bacteria used as starter organisms combine the positive images of fermentation and probiotic cultures [38]. In probiotic fermented dairy products, viability of most of probiotic strains are affected as a result of antagonistic interaction between starter cultures and probiotic strains, as well as acid production in these cultured products [31,39]. As a result to these factors, a new trend in producing probiotic non-fermented dairy products has emerged. Wide range of probiotic non-fermented dairy products are produced and marketed by far, such as cheese, ice-cream, and fresh milk [31,33,40].
For the maximum probiotic bacteria viability and optimal therapeutic effects, different types of food products were proposed as a carrier for probiotic bacteria by which consumers can take large amounts of viable probiotic cells. Yogurt, as a fermented milk product, is one of the most popular food carriers for the delivery of probiotic. Yogurt has long been recognized as a product with many desirable effects for consumers, and it is also important that most consumers consider yogurt to be ‘healthy’, add to that incorporation of probiotic bacteria, such as L. acidophilus and B. bifidum, into yogurt may add extra nutritional-physiological values [37,38]. Different types of yogurt and yogurt like products are manufactured around the world with different textures, including; natural-set yogurt, stirred yogurt, and drink yogurt, and these products differ greatly in their content of nonfat solids: 16–18%, 13–14%, and 11–12%, respectively [39].
Yogurt is a fermented milk product that has been prepared traditionally by allowing milk to ferment at 42–45◦C. Modern yogurt production is a well-controlled process that utilizes ingredients of milk, milk powder, sugar, fruit, flavors, colorings, emulsifiers, stabilizers, and standard pure cultures of LAB (Streptococcus\n\t\t\t\t\t\tthermophilus and L. bulgaricus) to conduct the fermentation process. S. thermophilus and L. bulgaricus exhibit a symbiotic relationship during fermentation process of yogurt, with the ratio between the species changing constantly. The pH of commercial yogurt is usually in the range of 3.7–4.3 [38]. Recently new yogurt products, known as “Bio-Yogurt”, have been manufactured by incorporating live probiotic strains in addition to the standard cultures, S. thermophilus and L. bulgaricus, into yogurt, since the recent discoveries in several aspects of bioscience support the hypothesis that, beyond nutrition, diet may modulate various functions in the body [32]. The Bio-Yogurt products have been formulated with different types of probiotic strains; mainly species of Lactobacillus and Bifidobacteria; include L. acidophilus; L. casei; L. gasseri; L. rhamnosus; L. reuteri; B. bifidum; B. animalis; B. infantis; and B. longum [32,34,35,41-43] Therefore, Bio-Yogurt is a yogurt that contains live probiotic cultures, the presence of which may give rise to claimed beneficial health effects. Different types of Bio-Yogurts are produced by far, including, plain, stirred, flavored, and fruits added Bio-Yogurts.
For the production of Bio-Yogurt, similar processing procedures of traditional yogurt are applied with the addition of live probiotic starter cultures. Heat treated, homogenized milk with increased protein content (3.6–3.8%) is inoculated with the standard starter cultures at 45◦C and incubated for 3.5-5h [32]. The most common procedures of incorporation probiotic bacteria to Bio-Yogurt include: (1) addition of probiotic bacteria together with standard starter cultures; (2) two-step fermentation, which includes the fermentation of milk first with probiotic cultures to achieve high levels of viable cells, and then addition of standard starter cultures to complete fermentation; (3) two batches fermentation, in which two separate batches of pasteurized milk are fermented, one with probiotic cultures and the other with standard starter cultures, and then the two batches are mixed together; (4) the use of a probiotic alone as a starter culture. In this situation, the time of fermentation is generally higher than regular yogurt production using non-probiotic starter cultures [32,44]. However, the use of the probiotic bacteria alone in the production of yogurt was not sufficient to produce high quality product, where the pH values and the final characteristics (pH values 4.9-5.5, with poor curd formation) of yogurt manufactured by using probiotic species of Lactobacilli and Bifidobacteria, were unsatisfactory [32]. Probiotic bacteria generally tend to exhibit weak growth and acid production in milk, which invariably leads to long fermentation times and poor quality product. This may be due to the sensitive character of the microorganisms in these Bio-products, which adds to the usual difficulties encountered with novel food production (i.e. unusual palatability and consequent limited consumer acceptability) [45]. The poor quality and sensorial characteristics of Bio-Yogurt products are important challenges in probiotic industry [38]. To overcome the problem of the poor quality, two-step fermentation with mixed cultures of the probiotic bacteria and standard starter cultures was suggested. The use of the mixed cultures in the two-step fermentation resulted in yogurt with better acceptability and sensorial quality, and these include longer time for probiotic species to grow and multiply with making use of the traditional cultures to impart the traditional and favorable organoleptic characteristics [45]. Also, it is important to consider the effect of probiotic bacteria addition on the product sensorial characteristics, since metabolites produced by probiotic bacteria may lead to undesirable sensorial effects [46].
Different levels of probiotic bacteria in Bio-Yogurts have been recommended and specified, in order to exert the claimed health effects and considered as probiotic products. The National Yogurt Association (NYA) of the United States specifies that 108 cfu/mL of lactic acid bacteria at the time of manufacture, are required to use the NYA‘Live and Active Culture’ logo on the products containers [47]. In Japan, the Fermented Milks and Lactic Acid Bacteria Beverages Association has specified a minimum of 107 cfu/mL of bifidobacteria to be present in fresh dairy products as a standard [48]. Therefore, maintaining the probiotic bacteria viability and survivability during products manufacturing and storage is a very crucial factor for effective probiotic products. Different factors have been found to affect probiotic bacteria viability in Bio-Yogurt products, include, pH, oxygen residues, product composition, storage temperature, antagonistic activity among probiotic strains and with standard starter cultures. For example, survival of L. acidophilus is affected by the low pH of the yogurt [43], also, the addition of any ingredients, such as fruits or fruits constituents, that lower pH in yogurt may contribute to reduce the survivability of L. acidophilus [34]. Rapid loss of viability of B. animalis subsp. lactis was reported with increasing percentage of fruit pulp added into yogurt base [49]. Yogurt with high fat content inhibited probiotic cultures, particularly B. bifidum BBI [39]. Also, as the probiotic bacteria are oxygen sensitive, oxygen residues in yogurt has an inhibition effect on probiotic bacteria viability [45].
Bio-Yoghurts supplementation with different substances has showed variable effects on probiotic bacteria viability. The supplementation of Bio-Yogurt with ascorbic acid improved the viability of L. acidophilus in yoghurts [45]. Oxygen scavenging effect of ascorbic acid is one of the possible mechanisms that may help to improve the viability of probiotic bacteria. Moreover, due to their buffering capacity, the addition of whey protein may enhance the viability of some probiotic bacteria, especially in yogurts with added fruit pulp. Also, the incorporation of prebiotics (indigestible carbohydrates, such as fructooligosaccharides and inulin) [40], and neutraceuticals combination (isoflavones, phytosterols and omega-3-fatty acids) [28, 35] in yoghurt formulations seemed to stimulate the viability and activity of probiotic bacteria. Generally, prebiotics selectively stimulate the growth and activity of probiotic bacteria [20]. It was reported that incubation period, incubation temperature and storage time of yogurts affect probiotic bacteria viability [60]. On the other hand, as a result to oxygen incorporation into yogurts during stirring fruit pulp into yogurt base, stirred-yogurts have lower probiotic bacteria viability levels compared to plain-yogurts. Also, addition of cysteine at 250 and 500 mg/L to yogurt was associated with higher viability of L. acidophilus during manufacture and storage while viability of bifidobacteria was adversely affected by the same levels in different starter cultures, whereas, at level of 50 mg/L bifidobacteria demonstrated better viability. However, in mixed cultures Bio-Yogurt products, antagonistic and symbiotic interactions among probiotic cultures and between probiotic and standard starter cultures are very important factors affecting probiotic bacteria viability. The probiotic cultures must be compatible with each other and with the standard starter cultures, since these micro-organisms could produce inhibitory substances that damage each other and affect probiotic bacteria viability [40,51]. Different pattern of interactions have been demonstrated among different probiotic strains, include, strong, weak, and lack of inhibition [40]. Establishment of suitable combinations of mixed probiotic cultures, to guarantee the maximum probiotic bacteria viability and avoid any inhibitory effect during yogurt manufacturing and storage, requires the assessment of the pattern and the extent of interactions among the probiotic strains and the probiotic strains with the standard starter cultures.
Ice-cream is a frozen dairy product, consists of a mixture of components, include, milk, flavoring, sweeteners, stabilizers, and emulsifiers agents [52]. Several ice-cream related products, such as plain ice-cream, reduced fat, low fat, nonfat, fruit, and nut ice-creams, puddings, variegated, mousse, sherbet, frozen yoghurt, besides other frozen products are manufactured and marketed around the world [53]. Smoothness and softness are among the important physical criteria of ice-cream, and these criteria are conferred by vigorous agitation during freezing to incorporate air into frozen product [54]. Ice-cream is a highly appreciated product by people belonging to all age groups, include children, adults, and the elderly public, and by all social levels. Also, the ice-cream low acidity results in increased consumer acceptance, especially by those who prefer mild products.
During the last few decades, new type of the ice-cream products have been introduced to the markets, these products were developed by incorporating probiotic cultures into ice-cream products. The incorporation of probiotic cultures into ice-cream resulted in adding value to the ice-cream product and being considered as a functional product, in addition to being a rich food from the nutritional point of view, containing dairy based material, vitamins and minerals in its composition [33,52]. As a result to the composition/structure, manufacturing procedures, and storage conditions, ice-cream and frozen dairy desserts demonstrated great potential for use as vehicles for probiotic cultures. The ice-cream freezing storage temperature and low risk of temperature abuse during storage has leaded to higher viability of probiotic bacteria [54,56]. The ice-cream composition, which includes milk proteins, fat and lactose, as well as other compounds, make ice-cream a good vehicle for probiotic cultures. Also, ice-cream relatively high pH values (5.5 to 6.5) lead to an increased survival of the probiotic bacteria upon storage. Several studies showed the suitability of ice-creams as a vehicle for probiotic bacteria [33, 53].
The general steps involved in probiotic ice-cream manufacturing are: mixing the ingredients involved (milk, milk powder, sugar, emulsifiers, stabilizers); pasteurizing; cooling to a temperature of around 37–40◦C, for the soured ice-cream, the freeze-dried starter cultures (usually yoghurt cultures) and the probiotic cultures is added; subsequent fermentation to a pH of 4.8–5.7, or the addition of a previously fermented inoculums containing both types of lactic cultures; cooling and keeping the mixture at 4◦C for 24h for the maturation. Ice-cream mix is produced at this point. The mix is subsequently beaten/frozen, in order to produce the final product, which is packaged and maintained frozen throughout transport, commercial distribution, and storage for consumption. During all these steps after freezing, the temperature of the frozen product should be strictly controlled [33,53].
During probiotic ice-cream development, the ultimate aim of processes optimization is to enhance and maintain the probiotic survivability, so as to guarantee the product functional efficacy [55,56]. This includes the consideration of all the challenges involved in the production of conventional ice-cream. These challenges include: the ingredients microstructure and colloidal properties and/or components used in the formulation; the control of the ice crystallization; the choice of appropriate stabilizers; control of the fat destabilization and the emulsifier functionality [53,55]. Also, the incorporation of probiotic bacteria into an ice-cream products must not affect the product quality criteria, including physico–chemical parameters, such as the melting rate, and the sensory features, which must to be the same or even better than a conventional ice-cream. Ice-cream beaten, commonly known as overrun, is a process by which the air is incorporated into the product. Overrun is an intrinsic and compulsory step in the ice-cream processing, as it has a crucial impact on the physical properties and sensory acceptance of the ice-cream product, including, body lightness and the formation of a smooth structure, influencing characteristics such as the melt down and hardness properties. In fact, too little air gives the ice-cream a heavy, soggy body while too much air brings a fluffy body [57]. Therefore, overrun is a parameter that should be monitored in ice-cream formulations [58]. The overrun step, as a result to oxygen incorporation into the product, seems to affect the survival of probiotic cultures during processing and storage [33]. However, there is limited information about the effect of the overrun levels adopted during the processing of ice-cream on the survival of probiotic bacteria as well as the sensory acceptance of this kind of product. Recent reports indicated that higher overrun levels negatively influenced probiotic cultures; therefore it was recommended that lower overrun levels should be adopted during the manufacture of ice-cream in order to maintain its probiotic viability through the shelf life [56].
A decrease in the viability of some probiotic species during manufacturing and freezing of probiotic ice-cream was reported as a result to cells damage by freezing and thawing, mechanical stresses of mixing and overrunning during manufacturing and thereby exert a negative effect on functional efficacy of probiotic bacteria in frozen products after ingestion [57]. Addition of inulin and oligofructose demonstrated higher viability of L. acidophilus and B. lactis in ice-cream due to prebiotic effect. It is also found that viability of these probiotic bacteria may vary depending on the sugar levels of ice-cream [59,60]. In probiotic ice-cream development, great attention should be given to the other ingredients that are used in the product formulation, especially fruit pulp/juice, which give the product the final flavor. Fruits or their derivatives with a pronounced acidic character should be avoided in ice-creams containing probiotic cultures, since this attribute could influence their sensory acceptance and also decreased the viability of the cultures [61] as its addition decrease pH values. One of the strategies to ensure probiotic bacteria survivability in acidic products is to select acid resistant strains. A recent study suggests the addition of chemical compounds with buffering capacity – carbonate, and citrate salts – at acceptable levels before or during the incubation, in order to eliminate acidic stress [33]. However, fruits and/or flavorings additives with mild and low acidity ought to be used in ice-cream.
Cheese is the generic name for a group of fermented and non-fermented milk-based dairy products produced and consumed throughout the world in a great diversity of flavors, textures, and forms [62,63]. An essential part of the cheese making process is the curd formation, which involves the conversion of liquid milk into a solid mass that contains casein and fat of the milk. This is achieved by the addition of rennet or acid production by cheese starter cultures to coagulate the casein gel. Curd formation in rennet set cases is carried out through the action of chymosin on the k-casein steric stabilizing layer of the casein micelle. In cheese making, curd formation is usually followed by several processes such as pressing, salting and ripening. Many cheeses, known as ripened cheeses, need an additional time to ripen under controlled environmental conditions to achieve their own sensory features, particularly flavor and aroma [64]. All cheeses, whether rennet or acid set, can be classified as soft, semi-soft (semi-hard), hard, or very hard cheeses according to moisture contents [63].
As a result to the cultural aspects and the technologies involved with fermented milks and yogurt production, include, relatively short fermentation time, low pH values, oxygen residues, and antagonistic activity of yogurt starter cultures against probiotic bacteria, these cultured products may not be the optimal food carriers for probiotic bacteria to human, as this evidenced by poor probiotic bacteria viability in commercial yogurts [43,51]. In this case, cheese provides a valuable alternative as a food vehicle for probiotic delivery. Cheese high protein content provides probiotic bacteria with a good buffering protection against the high acidic condition in the gastrointestinal tract, and thus enhances probiotic bacteria survival throughout the gastric transit. Moreover, the dense matrix and relatively high fat content of cheese may offer additional protection to probiotic bacteria in the stomach. Also, the relatively high pH values and lack of antagonistic effects of starter cultures, in rennet set cheese may exert optimal conditions to maintain probiotic bacteria viability during cheese making and storage [31]. Accordingly, several soft, semi soft (semi hard), and hard probiotic cheese products have been developed and marketed in the last few years. Jordanian probiotic soft cheese was developed from goat\'s milk using L. acidophilus and L. reuteri [31]. Cheddar-like cheese was produced by using B. infantis [65]; whereas, cheddar cheese was produced by using L. acidophilus, L. casei, L. paracasei and Bifidobacterium spp. [66]. Also, probiotic bacteria of Bifidobacterium, L. acidophilus and L. casei; and L. paracasei A13 were used to produce Argentinian Fresco Cheese, respectively [39,67]. Moreover, it was shown that cheddar cheese is a good carrier to deliver Enterococcus faecium into the gastrointestinal tract of human [68]. Viability of probiotic bacteria during cheese processing and storage is the major challenge associated with the development of probiotic cheese. Probiotic bacteria should be technologically suitable for the incorporation into cheese products so that to retain both viability and functional efficacy during processing on a commercial scale and throughout consumption [69]. Furthermore, from a food processing perspective, it is desirable that such strains are suitable for large-scale industrial cheese production and withstand the processing conditions [70]. With regard to the development of probiotic cheese, this means that such strains should be grown to high cell level before addition into the cheese and/or be able to maintain viability during the manufacturing and/or ripening step [31,64]. In addition, a probiotic cheese should have the same sensory and nutritional qualities as the conventional cheese; the addition of probiotic cultures should not cause any loss in cheese quality. In this context, the level of proteolysis and lipolysis must be the same or even better than cheese which does not have probiotic bacteria [31,66].
Most of the probiotic cheeses have been developed by the addition of probiotic bacteria into cultured cheese [67,71]. In such products, viability of most probiotic strains was affected due to the antagonistic interaction between cheese starter cultures and probiotic bacteria, as well as acid production in these cultured products [64,69]. Compared to cultured type cheeses and due to its manufacturing process, fresh soft cheese seems to be ideally suited to serve as a carrier for probiotic bacteria as it is an un-ripened cheese, during storage it is submitted to refrigeration temperatures, and its shelf life is rather limited [31]. Fresh soft cheese is a semi-hard cheese and is manufactured in the Middle East and along the shores of the Mediterranean Sea [62]. Most of the soft cheeses are usually made by addition of rennet enzymes to pasteurized milk with no addition of starter cultures. Its pH is almost the same of original milk pH (6.3- 6.5). Moreover, soft cheese is very popular in many parts of world, because of its soft texture and favorable organoleptical characteristics [31]. As a result of these characteristics, soft cheese represents a promising vehicle to deliver probiotic to human. A number of scientific papers reporting the development of fresh cheeses containing recognized and potentially probiotic cultures have been published, which described suitable viable counts and a positive influence on the texture and sensorial properties of these cheeses [31,67]. Method of addition of probiotic bacteria into cheese has a crucial effect in the probiotic viability and functional efficacy during cheese processing and storage. There are two options for the addition of probiotic bacteria during cheese processing. First, probiotic bacteria can be added before the fermentation, together with the starter culture; second, after fermentation. In the first option, the optimal initial inoculum of probiotic to be added and the amount of probiotic which are lost in the whey during its drainage must be evaluated according to the process. In the second option, cheese must be cooled directly after probiotic addition, as metabolic activities of starters and probiotic bacteria are drastically controlled and reduced at these low temperatures. However, other methods for the addition of probiotic bacteria in a semi-hard cheese are the freeze-drying and spray-drying methods. These methods enhanced probiotic viability during cheese processing and storage via the protecting probiotic bacteria against different undesirable conditions encountered cheese processing [72].
Even though there is no specified level of probiotic bacteria in foods that would guarantee the biological activity, but it is increasingly recommended to ingest 108 CFU/day [1]. Having in mind that portions of around 100 g of cheese are usually consumed daily, populations of about 106-7 CFU/g lead to an ingestion of 108-9 CFU/daily portion. Addition of prebiotic substances was one of the valuable measures taken to maintain and enhance probiotic viability in cheese products. For example, addition of oligofructose and/or inulin to petit-suisse cheese enhanced the viability of both L. acidophilus and B. animalis subsp. Lactis, while addition of eucalyptus honey reduced the viability level of both probiotic bacteria in the same cheese. The low oligosaccharides content of honey may lead to poor growth and viability reported [73]. Moreover, inulin helps to improve the growth and viability of various probiotic species in a number of different products [50,73].
Also, probiotic bacteria used in food products, such as Lactobacillus and Bifidobacterium species are: oxygen sensitive or anaerobic; and acid and bile sensitive in nature [74]. Hence, the presence of oxygen, acid and bile may represent a threat for their survival. Several techniques have been applied to enhance and maintain the viability of probiotic bacteria under harsh conditions typical in cultured dairy products and cheeses, including the selection of probiotic strains tolerant to oxygen, acid and bile, the addition of amino acids and peptides [75]. Another strategy for enhancing bacterial tolerance to stress such as temperature, pH or bile salts is a prior exposure to sub-lethal levels of the given stresses. Stress responses may be used to enhance the survival of probiotic bacteria in stressful conditions and to improve their technological properties [76,77]. Moreover, another alternative for protecting probiotic bacteria to oxygen stress is the use of selected strains of S. thermophilus with high oxygen consumption rate as starter for the production of cheeses [75]. Salting of the curd, by immersing it in brine or rubbing salt on the surface is a common step in the manufacture of several varieties of cheeses. In several types of cheeses, specially ripened types, salt is added for preservative and sensorial purposes. However, this slat has an inhibition effect on the growth and the viability of probiotic bacteria in cheese [51]. It is well established that salt level is drastically reduce probiotic viability, especially when salt level is higher than 4% [78]. Therefore, processing of cheeses with high salt content should be optimized to minimize this inhibition effect of slat. Another option is to find ways to protect the probiotic bacteria from the hostile environment. One alternative is micro-encapsulation or cell incubation under sub-lethal conditions [79].
The packaging system is another important factor that is affecting probiotic viability and stability, especially during cheese storage stage. In general, probiotic dairy foods, including cheese, are packaged in plastics films which have different levels of permeability to oxygen. This becomes an important factor because most of the probiotic strains used in food are either oxygen sensitive anaerobic in nature. Therefore, oxygen low permeability plastic films should be used to pack these functional products; alternatively, the practice of adopting other alternatives, such as the use of vacuum packaging can be followed [80].
Kefir is a traditional popular beverage consumed for thousands of years in the Central Asia and Middle East countries. It originates in the Caucasus Mountains in Central Asia. Kefir can be considered as natural probiotic fermented milk. It is an acidic-alcoholic fermented milk product, with uniform creamy consistency and a slight sour taste. Milk is fermented with kefir grains, small cluster of micro-organisms held together by a polysaccharide matrix named kefiran, and/or starter cultures prepared from grains [81]. Kefir grains look like pieces of coral or small clumps of cauliflower, which contain a complex mixture of lactic acid bacteria; Lactobacillus, Lactococcus, and Leuconostoc; acetic acid bacteria and yeast mixture [82]. Kefir grains usually contain lactose-fermenting yeasts; Kluyveromyces lactis, K. marxianus and Torula kefir; as well as non-lactose-fermenting yeasts Saccharomyces cerevisiae [81]. Yeasts are important in kefir fermentation because of the production of ethanol and carbon dioxide. L. kefiri is the dominant LAB in kefir, comprising about 80% of the LAB flora. The other 20% of the LAB flora in kefir comprises: L. paracasei subsp. paracasei, L. acidophilus, L. bulgaricus, L. plantarum, and L. kefiranofaciens [83].
The chemical and nutritional composition of kefir is variable and depends on the source and the fat content of milk, the composition of the grains or cultures and the technological process of kefir [84]. Kefir contains vitamins, minerals and essential amino acids that help the body with healing and maintenance functions and also contains easily digestible complete proteins. Kefir is rich in vitamins B1, B12, folic acid, vitamin K, and biotin, as well as calcium, magnesium, and phosphorus, beside essential amino acids such as tryptophan [83,84]. The benefits of consuming kefir in the diet are numerous. Kefir has frequently been claimed to be effective in improving several health and disease conditions, include cancer treatment, intestinal disorders, and promote bowel movement, constipation, flatulence, lactose intolerance [85]. Also, kefir antibacterial, anti-tumor, immunological, and hypocholesterolemic effects have been studied recently, and many reports indicated the efficacy of kefir products in possessing such effects [94,96-97].
Kefir beverages can be made from any type of milk; include, cow, goat or sheep, but commonly used is cow milk. Several substrates are produced in kefir aerobic fermentation includes lactic acid, acetic acid, CO2 alcohol (ethanol) and aromatic compounds. These substrates provide kefir with its unique sensorial characteristics: fizzy, acid taste, tart and refreshing flavors [83]. There are several methods of kefir production. The traditional and industrial processes are the commonly used methods. The traditional method of making kefir involves the direct addition of kefir grains into milk. The raw milk is boiled and cooled to 20-25◦C and inoculated with 2-10% (average of 5%) kefir grain. After 18-24h of fermentation, at 20-25◦C, the grains are separated from the milk by filtering with a sieve. Grains can be dried at room temperature and kept at cold temperature to be used in the next inoculation. Kefir milk is cooled before consumption [81, 83]. In the industrial process of kefir, different methods with the same principle are usually applied to produce kefir. The first step is milk homogenization to 8% dry matter, and heating at 90-95◦C for 5-10 minutes. Then cooling at 18-24◦C and inoculate with 2-8% kefir grains and /or kefir starters in tanks. Fermentation time is 18 to 24h. The coagulum is pumped and distributed in bottles. After maturing either at 12-14◦C or 3-10◦C for 24h, kefir is stored at 4◦C [81,83].
As mentioned earlier, dairy products are the main food carriers for probiotic bacteria to human. Limitations of these products such as the presence of allergens, high lactose and cholesterol contents, and the requirement for cold storage facilities have created the need to look for new probiotic product lines based on non-dairy substrates [88, 98]. Furthermore, the increase in the consumer vegetarianism throughout the developed countries generated an increasing demand for the vegetarian probiotic products, as well as the demand for new foods and tastes have initiated a trend in non-dairy probiotic product development [88, 89]. Accordingly, several ranges of non-dairy probiotic products have been developed and marketed in the last two decades. The market available non-dairy probiotic products include: fruits and vegetable, juices, non-dairy beverages, cereal based products, chocolate based products, meat…etc [88, 90-93].
Any new non-dairy probiotic food products should fulfill the consumer’s expectancy and demands for the products that are pleasant and healthy; accordingly, the development process would be increasingly challenging [90, 95]. According to [94], new product development is a constant challenge for both scientific and applied research, and it has been observed that food design is essentially a problem of optimization to generate the best formulation. For this purpose, industries need to determine the basic formulation for each product, and the optimum levels of each ingredient to obtain the best sensorial and physicochemical criteria, chemical stability and shelf life, and reasonable price.
Fruits and vegetables are considered healthy foods, as they contain several beneficial nutrients, such as minerals, vitamins, dietary fibers, and antioxidants. Unlike dairy products, fruits and vegetables lack allergens, lactose, and cholesterol, which adversely affect certain segments of the population [96]. Moreover, recent technologies advances have made alterations to some structural characteristics of fruits and vegetables matrices by modifying food components in a controlled way such as pH modification, and fortification of culture media, that might make fruits and vegetables ideal substrates for probiotic bacteria delivery to human [97] Accordingly, several type of probiotic fruits and vegetables products have been developed and marketed, such as fruits and vegetables juices, dried fruits, fermented vegetables, and vegetarian deserts [88,96-98].
As result to their pleasant taste and flavor, as well as acceptability by all age and economic groups, fruit and vegetables juices became one of the most studied, developed and consumed probiotic fruit and vegetable products [96,99,100]. Therefore, it is believed that there is a great potential in developing a new generation of non-dairy probiotic products through successful candidates that are chilled fruit juices and fermented vegetable juices [99,100]. Wide range of probiotic strains, mainly species of Lactobacillus and Bifidobacteria, such as L. acidophilus, L. casei, L. paracasei, L. rhamnosus GG, L. plantarum, L. fermentum, and B. bifidum have been widely used in the development of many fruit and vegetable products, specially juice products, include orange, pineapple, cranberry, cashew apple, tomato, cabbage, beet and carrot juices. These products have been tested for the suitability as carrier for probiotic bacteria, and the sensory acceptability by the consumer [96,99-101]. In the industrial scale, probiotic bacteria have been incorporated directly and in cell free form into these products. This practice was accompanied with the direct exposure of probiotic bacteria to the acidic conditions of juices and to other unfavorable process conditions, and consequently loose viability. Therefore, a special direct liquid inoculation system, that allows food producers to add the probiotic bacteria directly to the finished product, such as the innovated technology of Tetra Pak’s aseptic dosing machine Flex Dos that allows the bacteria to be added to liquids just before they are filled into the cartons, is recommended to overcome the problems of direct inoculation [89]. This innovation is expected to significantly boost the market for the probiotic beverages, which have so far been restricted by the delicate nature of the ingredient and concerns over the contamination. Another challenge encountered the development and marketing of probiotic juices is the juices flavor and aroma. For example, unpleasant perfumery and dairy aromas, as well as sour and savory flavors have been observed in juices inoculated with L. plantarum It has been suggested that the perceptible off-flavors of probiotic orange juice, that often contribute to consumer dissatisfaction, may be masked by adding 10% (v/v) of tropical fruit juices [99].
However, variable patterns of probiotic bacteria viability have been demonstrated in fruit and vegetable juices. It was observed that probiotic’s viability in different juices depends on the strains used, the characteristics of the substrate, the oxygen content and the final acidity of the product [45]. For example, when species of Lactobacillus and Bifidobacterium were added to orange, pineapple and cranberry juices, great differences were observed regarding the acid resistance, and all the strains survived for longer period in orange and pineapple juice compared to cranberry [96]. However, the micro-encapsulation technologies have been successfully applied using various matrices, such as agar, calcium pectate gel, chemically modified chitosan beads and alginates, to provide a physical barrier against unfavorable conditions to protect the probiotic cells from the damage caused by the external environment [100,102]. Vacuum impregnation is another technology applied to improve probiotic bacteria viability in fruit and vegetables products [103]. Using this technology, viability of L. casei was improved and sustained in dried apple slices for two months upon storage at room temperature. In this study, dried apple slices were immersed in probiotic cultures grown in liquid, usually natural juices, followed by applying a vacuum pressure of 50 mbar for 10 min, and then atmospheric pressure was restored leaving samples under the liquid for an additional 10 min period [97]. Moreover, fresh apple slices supplemented with L. rhamnosus GG was reported to represent a good vehicle for probiotic bacteria, as the probiotic bacteria maintained viability for 10 days at 2-4◦C [104]. Also, fermented table olive represents a potential carrier for delivery of L. paracasei IMPC 2.1 [91].
Even though, that cereal nutritional quality, compared to milk and meat, is inferior because of their lower protein content, deficiency of certain essential amino acids (lysine), low starch availability, anti-nutrients substances (phytic acid, tannins and polyphenols) and the coarse nature of the grains, cereal grains are still considered as one of the most important food sources of protein, carbohydrates, vitamins, minerals and fiber for large segments of people all over the world [90]. Furthermore, cereal grains are good source of non-digestible carbohydrates that besides promoting several beneficial physiological effects can act as prebiotics that selectively stimulate the growth of Lactobacilli and Bifidobacteria in the colon [95]. Whole grains are also sources of many beneficial phytochemicals, including phytoestrogens, phenolic compounds, antioxidants, phytic acid and sterols [105].
Usually cereals are consumed either in a fresh or fermented states. There are a wide variety of traditional non-dairy fermented beverages produced around the world, most of them are non-alcoholic cereal beverages [101]. Even though, the non-dairy fermented cereal products have long been created throughout history for human nutrition, it just recently that probiotic characteristics of microorganisms involved in cereal foods fermentation have been evaluated. Examples of the traditional non-dairy cereal- based fermented beverages include, Boza, Tarhana, Kishk, Chicha, Kisra, Kenkey…etc. [89].
Several studies were carried out to develop probiotic cereal products, especially beverage type. The development of cereal based probiotic products requires the evaluation of the suitability of cereals as growth medium for probiotic bacteria. Probiotic bacteria, especially the strains of Lactobacillus and Bifidobacteria, have been recognized as complex microorganisms with high nutritional requirement, such as fermentable carbohydrates, amino acids, B vitamins, nucleic acids and minerals [74]. As mentioned earlier, cereals are good source for proteins, carbohydrates, vitamins, and minerals, beside their prebiotic content. These constituents may make cereals a suitable medium for probiotic bacteria growth. Beside that, fermented cereals, as a result to the fermentation process, may have more available nutrients for probiotic bacteria growth, such as improved protein quality and level of lysine, some amino acids may be synthesized, decreased level of carbohydrates as well as some non-digestible poly and oligosaccharides, and increased availability of group B vitamins, optimum pH conditions for enzymatic degradation of phytate and release minerals such as manganese (which is an important growth factor of LAB), iron, zinc and calcium [90]. Therefore fermentation of cereals may represent a cheap way to obtain a rich substrate that sustains the growth of probiotic bacteria. However, in the fermented cereal-based probiotic products, the antimicrobial activity of the LAB of the fermented cereals against added probiotic bacteria must also be considered and evaluated [92].
Several studies have been conducted to evaluate the suitability of different cereal grains to enhance probiotic bacteria growth and maintain their viability [88,92,108]. The oat-based, non-dairy products have been shown to enhance the survival of the probiotic strains L. reuteri, L. acidophilus and B. bifidum, all of human origin, upon storage at 6◦C up to 30 days. These products were fermented by the three strains with and without the commercial yogurt culture. Products fermented in presence of yogurt culture showed lower probiotic bacteria viability compared to product fermented with probiotic bacteria solely. Yosa, a new probiotic oat-based fermented food, similar to flavored yogurt or porridge, contains LAB and bifidobacteria [90]. Yosa is considered as a healthy food due to its content of oat fiber and probiotic LAB, which in combination with the effect of b-glucane might reduce cholesterol and the effect of LAB in maintaining and improving the environment in the intestinal balance of the consumer. Maize, one of the most important sources of food for millions of people, particularly in Latin America and Africa. A maize porridge made of maize flour and barley malt, with high energy density and low viscosity, was fermented with four probiotic strains L. reuteri, L. acidophilus (2 strains) and L. rhamnosus GG. All strains exhibited a strong growth upon fermentation and storage [88], suggesting that maize porridge supplemented with barely malt is a good medium for probiotic growth. Also, and as a result to the desirable fruity flavors of fermented maize foods, probiotic fermented maize products could have a good world-wide acceptance. Rice is the major cereal in Asia, and its products could be an economical and beneficial medium to develop probiotic foods. The growth of four probiotic bacteria (L. acidophilus, L. pentosus, L. plantarum and L. fermentum) was found to be higher in germinated rough rice powder (5%, w/w) mixed with water than in only rice powder with added NaCl. Germinated rice grains found to have an increased content of reducing sugars, total protein and vitamins, mainly B vitamin, which is a very important element required for the growth of L. plantarum [74].
Soybean, the most important legume in the traditional Asian diet, is rich in high-quality protein. The products of soybean play an important role in the prevention of chronic diseases such as menopausal disorder, cancer, atherosclerosis, and osteoporosis [107]. Experiments studying the survival of probiotics indicate that soy products, include, soymilk, soy-based yogurt, vegetarian frozen desert, fermented soy tempeh, and soy cheese, are a good substrate for the growth of probiotic bacteria [88,92,106,109]. Soy yogurts were prepared with a yogurt starter in conjunction with either the probiotic bacteria L. johnsonii, L. rhamnosus GG or human derived Bifidobacteria. Probiotic frozen vegetarian soy deserts were developed with the incorporation of L. acidophilus, L. rhamnosus, L. paracasei ssp. paracasei, Saccharomyces boulardii and B. lactis [108]. The neutral pH of the frozen soy dessert improved the probiotic survivability since some probiotic organisms are susceptible to inactivation when stored in acidic conditions [31]. Moreover, it was reported that soymilk fermentation with probiotic bacteria (strains of Lactobacillus and Bifidobacteria) increased the antioxidative activities of the fermented soymilk, and this further increases the potential of developing a probiotic diet adjunct with probiotic fermented soymilk [88]. Recently, a new probiotic soy based cheese was developed on the basis of Chinese sufu [106]. The soy cheese was made from soymilk fermented with soy cheese bacterial starter cultures and L. rhamnosus. The probiotic strain showed good growing pattern during soy cheese fermentation, and good survivability upon storage
Meat is a highly nutritious food with a high degree of nutrients bioavailability and consumers have a high degree of preference for its taste, flavor, and texture. Meat had shown an excellent vehicle for probiotics as a result to meat composition and structure. Furthermore, meat was found to have a protection effect on LAB against the lethal action of bile [109]. One of the most studied and processed probiotic meat products is the dry fermented sausages without heating. Beside the high nutritional value, the characteristics of this type of meat product make it an ideal food matrix for probiotic delivery to human, as, it is a fermented product so the addition of probiotic bacteria will not alter the product sensorial characteristics, also, it is not heat treated, and so the viability of probiotic bacteria will not be reduced. These fermented products are prepared from seasoned, raw meat that is stuffed in casings and is allowed to ferment and mature by LAB starter cultures. The currently commonly employed LAB strains in meat starter cultures include L. casei, L. curvatus, L. pentosus, L. plantarum, L. sakei, Pediococcus acidilactici and P. pentosaceus [110]. The incorporation of microorganisms that have probiotic criteria is receiving increasing interest. However, few reports so far are available concerning the incorporation of probiotic bacteria into dry fermented sausages. L. gasseri JCM1131 has been demonstrated to be useful as a potential probiotic strain for application in meat fermentation and improving its safety [111]. The efficacy of L. rhamnosus FERM P-15120 and L. paracasei subsp. paracasei FERM P-15121 has also been reported, as potential probiotics in meat products [112]. A mixed culture of the traditional starter culture and a potential probiotic culture of L. casei LC-01 or B. lactis Bb-12 have been successfully employed in sausage production [113].
The importance of using probiotic bacteria from the meat dominant strains supports the demand for higher numbers of viable cells at the time of consumption, which is a prerequisite for the probiotic to insure beneficial effects on the host. Furthermore, the use of a probiotic starter culture would prove superior in providing more safety, taste and health benefits, as compared to the traditional cultures [114]. LAB strains, include L. acidophilus, L. crispatus, L. amylovorus, L. gallinarum, L. gasseri, and L. johnsonii, were found to be suitable for meat fermentation and to enhance product safety [111]. Also, it has been reported that the selection of L. plantarum and L. pentosus isolated from Scandinavian-type fermented sausage as a promising probiotic meat starter cultures [121]. Moreover, L. plantarum and L. curvatus strains isolated from Greek dry-fermented sausages were resistant to 0.3% bile salts [116].
Various studies have shown that probiotic organisms survive poorly in fermented foods [117]. Nonetheless, probiotic organisms may be encapsulated by the sausage matrix consisting of meat and fat. Alginate-microencapsulated probiotics (L. reuteri and B. longum) may be an option in the formulation of fermented meat products such as sausages with viable health-promoting bacteria; nevertheless, their inhibitory action against some pathogen organisms could be reduced [118]. B. longum and L. reuteri encapsulated in Alginate were a suitable option for this purpose. Recently, B. longum was successfully protected in-vivo and in-vitro by encapsulation in innovated encapsulation material of succinylated β-lactoglobulin tablets [119].
Chocolate is one of the most popular products all over the world, due to its delicious taste and flavor, high nutritious energy, fast metabolism and good digestibility. The presence of cocoa butter, milk and milk based materials, as well as sugar in its composition can be the warranty of an appropriate ingestion of proteins, carbohydrates, fats, minerals and vitamins [120]. Chocolate in its original form has long been known to lift mood, increase mental activity, to control appetite, and improve heart health. However, the high sugar content of conventional brands has raised concerns that their consumption is contributing to the current obesity epidemic, to osteoporosis development in older women, and the raising diabetes incidence in the Western industrialized nations. Nowadays, one of the most important trends in chocolate manufacturing is originated by the consumers’ demand of functional or health-promoting chocolate, i.e., chocolate that not only do not adversely consumer health, but also remedy or prevent illnesses such as heart disease, osteoporosis, cancer, diabetes…etc. [121,122] Chocolate itself is a functional food, as it contains sufficient polyphenolic antioxidants and flavonoids compounds. These beneficial compounds in chocolate have been attributed to chocolate health beneficial effects. However, it is now possible for manufacturers to create functional foods by fortifying and enhancing their products to give them added health benefits have never been possible before, by incorporating probiotic bacteria to chocolate products [120] Developing a Probiotic chocolate product that is affordable and also nutritional for many more people is a challenge. The application of probiotic bacteria into chocolate could offer a good alternative to common dairy products, and allow broadening the health claims of chocolate based food products. Indeed, recent market research on functional food has shown that, in relation to chocolate, digestive health was one of the most important drivers of consumer acceptance [122,123].
The development of probiotic-containing chocolate involves a good understanding of the selected probiotic strains, the chocolate manufacturing process and the different critical points of the process for probiotic survival, as well as the application of specific protective technology [123]. Viability of probiotic bacteria in a product at the point of consumption is an important consideration for the efficacy, as they have to survive during the processing and shelf life of food and supplements, transit through high acidic conditions of the stomach and enzymes and bile salts in the small intestine [95]. Moreover, the sensorial acceptability of the product from the consumer is another limiting factor that determines the success of the product [124]. A few numbers of attempts were made to develop probiotic chocolate products so far. Recently, a chocolate mousse was developed by using probiotic and prebiotic ingredients. Probiotic and synbiotic chocolate mousses were supplemented with L. paracasei subsp. paracasei LBC 82, solely or together with the prebiotic ingredient inulin [122] It was shown that the chocolate mousse was an excellent vehicle for the delivery of L. paracasei, as it enhanced probiotic bacteria growth and viability during chocolate mousse processing and shelf life, and the prebiotic ingredient inulin did not interfere in its viability, as well as the addition of the probiotic microorganism and of the prebiotic ingredient did not interfere in the sensorial preference of the product. Moreover, another chocolate product was evaluated to support the growth and survivability of L. rhamnosus IMC 501 and L. paracasei IMC 502 mixed 1:1 (SYNBIO). The survival and viability of probiotics were determined during the product processing and shelf-life. The values of viable probiotic bacteria showed that this product could represent an ideal vehicle for probiotic bacteria to human [123].Furthermore, a chocolate product has been evaluated as a potential protective carrier for oral delivery of a microencapsulated mixture of L. helveticus CNCM I-1722 and B. longum CNCMI-3470 [124], the data in this study indicated that the coating of the probiotics in chocolate is an excellent solution to protect them from environmental stress conditions and for optimal delivery.
Spasticity is one of the common symptoms in a wide range of neurological conditions, and it needs multidisciplinary approach for best management. This chapter provides an excellent paradigm to incorporate many of the key elements fundamental to the management of chronic conditions and it is of relevance to those who work in spasticity rehabilitation. This chapter presents a comprehensive view about rehabilitation with these subtitles:
Assessment of the individual with spasticity
Provision of education and promoting self-management
Physical management of spasticity(physiotherapy or occupational therapy)
Orthoses
Pharmacological intervention
Setting up a service
Accurate assessment of spasticity is the starting point to make a proper and valuable plan for this route. In addition to assessing physical changes, resistance to movement, weakness, and contractures, the impact of spasticity on the activities of daily life should be considered as well. These assessments should also be carried out in the follow-up visits. In some references, it is recommended to perform the assessments by a professional in this area in a multidisciplinary visit with a team of specialists and clinicians instead of assessments by different specialists in several visits. The assessment consists of two parts: history and physical examination.
The ultimate goal of assessment of history is to provide a thorough history that encompasses the impact of the disease on the patient’s communications and interactions with the environment and also covers all aspects of the disease. Therefore, the provision of a checklist is recommended (Appendix 1). In addition to the suggested questions, the answers to these two questions are very important in history taking and should be included in the treatment plan: Does the spasticity contribute to improving your performance? And is this spasticity a local problem or a generalized one?
The physical examination involves three steps, as follows.
For observation, it is recommended to evaluate the items of posture, alignment, presence of spontaneous spasms, seating if applicable, movement patterns when moving (e.g., walking, transferring or picking up objects), and pressure sores. However, observation alone is not enough and outcome measurements (Appendix 2) such as timed 10-meter walk test and goniometry are useful.
The grading scale of the Medical Research Council (MRC) (Table 1) can be used to assess both weakness and spasticity. However, its application in severe to moderate spasticity is difficult.
Grade | Definition |
---|---|
0 | No contraction |
1 | Flicker of contraction only |
2 | Active movement with gravity eliminated |
3 | Active movement against gravity |
4 | Active movement against gravity and resistance |
5 | Normal power |
Medical Research Council (MRC) grading of muscle strength.
Trunk and limb spasms are evaluated in this step. This assessment is usually performed using the Modified Ashworth scale. However, it may fail to distinguish between neuronal and non-neuronal causes of spasticity [1]; thus, the items addressed in Table 2 should be noted to avoid misinterpretation [2]. It is effective to use the Tardiu scale [3] to differentiate between the neuronal component and the non-neuronal one because of the evaluation at different velocities [4]; however, it is more time-consuming than the Ashworth test. It should be noted that the suggested tests are specified for spasticity evaluation in limbs, and if one of the patient’s chief complaints is trunk spasticity, the verbal or visual analog scales can be used as well as measuring the distance between two fixed points on the trunk in fast and slow trunk flexions by using a tape.
Perform three passive movements only and record the score of the resistance felt on the third movement |
The score is taken within the available range |
Move the limbs in the best alignment possible, record position and use when repeating measures |
Regulate the speed by counting 1001, 1002, 1003 |
Recommendations to standardize the measurement of the Ashworth scale.
It is important to use outcome measures in clinical evaluation; however, it is always challenging to maintain a balance between test simplicity and speed with its reliability and validity [5], so different tests and methods have been suggested with respect to the disease diagnosis. In this book, we recommend the outcome measure of the National Hospital of Neurology and Neurosurgery (NHNN) in London with a few modifications [2], which is typically used for patients with moderate to severe spasticity (Appendix 2).
When the assessment is over and the treatment plan is being outlined, any physician should ask himself an important question: “why should I treat this spasticity?” and the more important question is “what are the patient’s expectations of this treatment?” So the ultimate goal should be discussed with the patients and their caregivers to expect a realistic outcome. Since these goals are different for each patient, the following desires can be addressed: sitting comfortably in a wheelchair, adequate and comfortable night sleep, easier catheterization for bladder drainage, etc.
Different algorithms [6, 7, 8] have been developed for the evaluation of and therapeutic approach to spasticity; one of the most applied of them has been developed by Stevenson et al. [2] and is presented in Figure 1.
Therapeutic approach to spasticity.
Nowadays, it has been found that the patient’s awareness of the disease and the situation he/she is dealing with promotes the therapeutic process and interventions. This view and its results have also led to the development of courses known as Expert Patient Programmes [9]. The patient and his/her caregivers’ understandings of the medical conditions and therapeutic interventions are crucial and effective to the treatment and therapeutic protocol selection. This is especially because different therapeutic interventions for spasticity do not have a linear nature and several treatments are sometimes considered for the patient at the same time (Figure 1).
To improve the spasticity treatment efficacy, some instructions should be presented to the patient, either verbally or using a written material [10]. These instructions include the following:
Maintaining movement and adequate positioning and B) Recognizing and preventing factors that may aggravate or trigger spasticity and spasms.
Maintaining movement and adequate positioning:
A main factor in the spasticity treatment is to maintain the joints’ range of motion, which should be performed by the patient or his/her caregiver. Moreover, maintaining muscle length is the second factor that is usually achieved by stretching or splinting [8]. Thus, sitting and standing positions are also critical.
Recognizing and preventing factors that may exacerbate spasticity and spasms:
Elimination of unwanted sensory triggers is an important factor in spasticity reduction. Naturally, cutaneous and visceral triggers (Table 3) regulate the interneuronal activity by signaling to the spinal cord. Elimination and dysfunction of some modulating pathways can inhibit polysynaptic reflexes (such as flexor withdrawal) and cause spasm [11].
Cutaneous stimuli | Visceral stimuli |
---|---|
Skin lesion (red or inflamed skin, broken skin, infected skin, pressure sores, ingrown toenails) | Bowel and bladder dysfunction: for example, constipation, overflow or diarrhea, infections, retention or incomplete emptying |
Tight-fitting clothes or urinary leg bag straps | Any systemic or localized infection |
Uncomfortable orthotics or seating systems | Deep-vein thrombosis |
Sensory stimulations that may aggravate spasticity.
Similarly, abnormal activities of spinal cord circuits induce discharges in motor neurons innervating several muscles, thereby causing a concurrent contraction of these muscles and aggravating spasticity [12, 13]. Sometimes, some patients are aware of such stimuli exacerbating their symptoms (e.g., bowel habit) while having no clue how to modulate or reduce them. The patients should consider the following:
1. Optimization of bladder and bowel management. Any defecation alteration including urinary retention, infection, constipation, or diarrhea can exacerbate the symptoms. Even the mild infection (e.g., Candida) can aggravate the symptoms.
2. Maintaining skin integrity. Avoiding any skin irritation, infection, and pressure sores is effective in spasticity reduction. So skin examinations, especially in the vulnerable areas including the areas under pressure or under orthosis, as well as preventing ingrown toenails and deep-vein thrombosis are needed.
Sometimes, there are individual factors that each patient gradually realizes (e.g., in some women, symptoms exacerbate during menstruation period). Knowledge of some of these risk factors is important in treatment choice. In some cases, elimination of some of these factors or waiting for a few days (e.g., in menstruation period) and or a temporary rise in the drug dosage is very effective in solving the patient’s problem.
Another point of patient education is that the weakness and spasticity are concomitant [2]; so the patient should know that sometimes the weakness becomes more pronounced by medication use and subsequent spasticity reduction while patients consider this effect as a drug side effect or lack of response. So, in case the spasticity is an effective factor in preserving some of the patient’s functions (e.g., standing up and going to the bathroom in the morning), the medication should be taken after the desired activity (going to the bathroom).
Patients should receive written information on the medication dosage, side effects, and follow-up tests for the response to treatment. There should be a telephone number in the form for convenient communication with the health care center or the physician.
The key to a satisfying treatment for spasticity is to educate the patient properly and ensure that the patient follows the instructions correctly. Also, as spasticity changes during the treatment, treatment regimens should change with the patient’s condition and be flexible. Proper patient management requires physiotherapy initiation immediately after the disease diagnosis and at regular intervals throughout the disease course, depending on the patient’s condition and the diagnosis made by the treatment team. On the other hand, assessment and differentiation between the neuronal and non-neuronal (connective tissue, joint component, muscle, and tendon) causes of hypertonia are critical because the treatment of non-neuronal [14] (passive) causes involves physical therapies such as stretching and splinting; these problems do not respond to medical treatments.
The goal of physical management is to maintain and even improve the performance level and prevent the problems secondary to spasticity. In fact, spasticity reduction is not always a treatment goal, as in some cases maintaining the patient’s function requires a little spasticity and increased tone. Therefore, physical management focuses on the performance, discomfort and pain relief, and prevention of secondary complications including contractures and pressure ulcers. The key goals of a physical management plan include the following [2]:
Maintaining the viscoelastic characteristics of tissues including tendons, muscles, and joints to prevent contractures. This goal is achieved through active and passive movements as well as standing and stretching with splints.
Controlling the spasticity and spasm so that they will not be self-perpetuating; for example, using techniques and methods in the situations and positions exacerbating the symptoms.
Maintaining the individual’s level of performance. It can be achieved by strengthening activities and keeping cardiovascular fitness.
Evaluation of spasticity as a positive factor in the patient’s function. But a balance should be maintained between the benefits and spasticity-induced complications.
Generally, there is no single physical modality and the treatments are parallel and concomitant, depending on the patient’s conditions. In the following, the treatment options will be discussed in detail.
Standing is considered as a therapeutic option since it activates the anti-gravity muscles, improves flexibility, reduces contractures, modulates the neuronal component of spasticity, reduces sensory inputs and lower limb spasms, and has positive psychological effects [15, 16, 17, 18]. Regarding the duration and frequency of this physical therapy, studies have suggested a duration of between 30 minutes and 1.5 hours while most patients have performed this exercise for 40 minutes and with a frequency of three to four times a week [18, 19, 20]. Remember that the duration and frequency depend on the patient’s condition; so, the decision should be made based on this factor. However, at least 30 minutes of standing seems to be reasonable. The best standing position is in an extended posture with neutral alignment of the trunk, pelvis, and lower limb joints, carried out actively by the patient himself/herself or by using standing aids including Oswestry standing frames, motorized or hydraulically assisted standing systems, standing wheelchairs, or at least a tilt table (according to the patient symptom severity respectively) [2]. In all these cases, hypotension is the most notable complication, which can be prevented by arrangements such as avoiding sudden position change or by using compression stockings.
In most of the cases, patients with spasticity are advised for spasticity reduction and less attention is paid to muscle weakness, and sometimes strengthening exercises are not prescribed because of the concern for spasticity exacerbation [21]. It is recommended, to the extent possible, to perform active exercises in order to increase the strength, re-educate movement patterns, and improve cardiovascular fitness. The outcomes achieved by these exercises are not usually observed in passive exercises. Nowadays, it has been found that not only is antagonist muscle weakness effective in spasticity, but also an imbalance between agonist and antagonist muscles exacerbates the symptoms and causes atrophy [21]. The movement patterns should also change; in fact, proper movement patterns should be instructed. At the same time with limb exercises, the alignments of the trunk and pelvic girdle should be maintained. These exercises alter muscle functions and structures [22]. The strengthening recommendations should be realistic and close to the patient’s daily life activities and include all the involved muscles [23, 24]. Although no specific protocol has been suggested for this kind of patients, most studies recommend the protocol adapted from the sport sources. These traditional training rates are a load of 60–80% of one repetition maximum (the maximum load that can be lifted once), three sets of 10 repetitions carried out three or four times a week.
Alongside these exercises, cardiovascular fitness exercises have been recommended in various papers [25, 26]. Because these exercises are being neglected in these patients due to their inactivity especially.
The task-focused active-use therapy techniques such as the constraint-induced movement therapy can sometimes be used for upper limbs. The techniques should be used in an intensive program over a short period (e.g., 4–8 weeks) [27].
When the patient cannot move his/her limb, passive movements can be carried out by another person. In passive movement, generally, all the body joints should be moved in their ranges of motion daily. According to the studies, it seems that using passive movements can be effective in changing spasticity pattern, alleviating secondary non-neuronal complications, and improving positioning [2]. It is recommended to perform the passive movements daily, and it can be carried out before the patient repositioning. These movements should be safe and comfortable for both the patient and caregiver. Spasmolytic medication taking in 20–30 minutes before the movements can be helpful [2]. Sometimes sudden stretching can exacerbate the spasm, so the movements should be performed at slow speed. Skin irritations can cause symptom exacerbation as well; thus, the best way is to desensitize the skin on a gradual basis or handling the limb on top of clothes. Grabbing and holding the ball of the foot should be avoided because it is usually a sensitive point for these triggers and better not to be touched [2]. Moreover, the movements should be carried out with the best alignments of the muscles and joints, overstretching should not occur, and stereotypical spasticity patterning (e.g., flexing the hip in the midline rather than in adduction and internal rotation) should be avoided.
The critical point is that after the movements are over, the patient should be positioned properly. The position should not be the same as the previous position caused by spasms to keep the benefits of the movements [2]. Usually, these movements are not performed by the physician or therapist because it is time-consuming and is not cost-effective. So in addition to providing written material on the right techniques for the patient and caregivers, assistance appliances such as continuous passive movement machines (CPMs) or lifters (hoist) can also be used [2].
Typically, with a 2-day immobilization, muscle changes initiate, including muscle shortening and atrophy, muscle compliance reduction, and increasing the ratio of collagen to muscle fibers [21]. Following these changes, there will be an increase in the sensitivity of muscle spindles to stretching, which can exacerbate the neuronal component of spasticity and subsequently the non-neural component [28]. On the other hand, stretching induces actin and myosin synthesis; as a result, the number of sarcomeres as well as the muscle length increases [21, 29]. So far, there is no agreement on the duration and frequency of stretching exercises but the following protocol can be considered for the daily schedule [30, 31].
It is suggested to administer the stretching according to the patient’s daily schedule and his/her posture [2]. The stretching can be carried out actively or passively (by someone else or with FES). We can use the positioning, for example standing, sitting, or lying down with using splints and orthosis, to achieve a prolonged stretching. Another important point is that while stretching a muscle, the antagonist muscle shortens, so there should be a balance in the stretching schedules for all the muscles [2, 32]. Regarding the duration of stretching, studies have suggested 20, 30, or even 60 minutes. So, there is no single protocol [30], but it seems that the efficacy increases with longer durations. Also, it seems that stretching before the exercises has a more favorable effect.
The patient should be given written instruction on stretching. Stretches should include the back muscles, quadriceps, hip flexors, hip adductors, hamstrings, calf muscles (gastrocnemius and soleus), wrists, and fingers, and should be performed actively or passively. The therapist should modify the stretching based on each patient’s condition.
As well as improving the effective stretching and subsequent maintaining of range of motion, correct positioning also helps in altering the spasticity pattern, modifying asymmetry, and decreasing the risk of pressure-induced skin injuries [33]. The golden key to good positioning is to change the position during the day. An ideal position is important in both lying and sitting; moreover, the presence of exacerbating factors and triggers (e.g., pressure sore, pain) is critical in position selection. Performing passive exercises before positioning is helpful; for example, when the patient tries to use a T roll for the leg flexion position, performing several knee and hip flexions and bending the hips and knees up toward the chest and abdomen facilitate this position [34].
In correct positioning, muscles should be stretched and longer than usual. For example, these are the suggestions to improve the positioning in a patient with continuous spasticity-induced hip adduction: The patient should monitor his/her sitting position and try to keep his/her knees apart while sitting so that he/she does not get accustomed to the wrong position. The impact of trunk and pelvis positions on the legs should be evaluated. In a flexed posture with a posteriorly tilted pelvis, the legs tend to be in internal rotation and adduction; so, having a firmer seat base, a contoured cushion, or extra trunk support may facilitate a more anteriorly tilted pelvis position, trunk extension, and better lower limbs alignment. In patients unable to reduce adduction, using aids including a pummel, rolled-up towel, cushion or T roll can help in reducing the adduction.
In patients suffering from spasticity, the sitting position should be modified to improve the performance, accommodate to contractures and deformities established, maintain comfort, and reduce fatigue [35, 36]. The main requirements for a good sitting position are a firm seat base and backrest with subtle changes by altering the seat base to promote an anterior tilt of the pelvis to help in achieving hip flexion, abduction, and external rotation as well as trunk extension.
Patients with weakness in the trunk and neck extensors can use the tilt-in-space systems [37, 38], where the patient seat has a reclining at the back and flexion at the hip. In this system, hip flexion decreases the extension tone and spasticity as well as providing support for the patient’s back (by the backward movement of the backrest). Also, these seats improve kyphosis and breathing of the patients and reduce fatigue and pressure ulcers.
As the patient’s spasticity status changes throughout the treatment, it is necessary to re-evaluate the patient’s sitting position.
Orthoses or splints are tools for improving limb performance and preventing deformity. These appliances are usually custom-made [39]. Non-removable splinting devices made of plaster or casting tape are referred to as “casts.” Casts are also a type of splint. Orthoses are used for the following treatment goals [27, 39]:
Providing control over the joint’s range of motion and thus improving its performance.
Maintaining prolonged stretches on the muscle’s tendon to alter or modify the changes occurred in tissues.
Modifying deformities established (e.g., using heel raise in leg length discrepancy).
Changing the neuronal component of spasticity through prolonged stretches and sensory input alteration.
Increasing the patient’s comfort.
Correction of the posture.
Correction of upper extremity performance.
Improving walking efficiency.
In children, preventing hip migration or slowing its progress.
In administering orthoses, in addition to discussing the treatment goals with patients, the method of use, duration, and times of use should be discussed as well. In each visit, the patient should be asked about pain, discomfort, and sleep disorder, while muscle wasting and the places under pressure by orthosis should be examined. Incorrect orthosis usage and feeling discomfort with orthosis use can exacerbate the symptoms and cause new deformities. There is no contraindication for administering orthoses; however, some problems addressed in Table 4 can limit the use of splints, so these points should be noticed during the follow-up visits and proper solutions should be considered [2].
Sensory impairment | Uncontrolled epilepsy |
---|---|
Unstable intracranial pressure | Heterotrophic ossification |
Poor skin condition | Edema |
Vascular disorder | Acute inflammation |
Fracture or severe soft tissue injury | Medically unstable |
Behavioral/cognitive disorders | Frequent spasms |
Access to limb required for medical purposes |
Precautions for the use of splints or orthoses.
The most common splints based on the usage area are discussed here according to the evidence from different sources and guidelines. Evidence grading is according to Tables 5 and 6 [40]. However, some of the splints are not mentioned here, we did not intend to deny their effects but only the splints with the best evidence are discussed.
Quality of evidence | Grading | Characteristics |
---|---|---|
High | A | Based on consistent results from well-performed randomized controlled trials, or overwhelming evidence of an alternative source, for example, well-executed observational studies with strong effects |
Moderate | B | Based on randomized controlled trials where there are serious flaws in conduct, inconsistency, indirectness, imprecise estimates, reporting bias, or some other combination of these limitations, or from other study designs with special strengths |
Low | C | Based on observational evidence, or from controlled trials with several very serious limitations |
Very low | D | Based on case studies or expert opinion |
GRADE quality of evidence grading.
Strength | Grade | Benefits and risks |
---|---|---|
Strong | 1. “It is recommended. ..” | Benefits appear to outweigh the risks (or vice versa) for the majority of the target group |
Conditional | 2. “It is suggested. ..” | Risks and benefits are more closely balanced, or there is uncertainty in likely service user values and preferences |
Strength of grade.
The following advice is suggested to correct contractures [40]:
It is possible to use casts at the end of the range of motion for acute brain injury and stroke patients to improve the range of motion (2C). The cast should be replaced every 5–7 days. Use the cast for a 2- to 12-week period.
In severely spastic patients, we can use casts with botulinum toxin injection (2B). The cast should be replaced every 5–7 days. Use the cast for a 2- to 12-week period.
Using adjustable ankle splints at the end of the range of motion improves the joint’s range of motion (2C). Splints are used 6–23 hours a day for 2–12 weeks and should be adjusted with improvements at the end of the range of motion.
While using non-custom-made splints, necessary precautions should be taken to prevent pressure sores (2D).
Contracture prevention [40]:
Using ankle casts at the end of dorsiflexion range can prevent contractures in ABI patients (2C). Primary casts should be replaced every 5–7 days depending on the change in the range of motion until the patient can maintain the plantar grade position. The last cast should be used as a bivalved plantar grade cast for 18 hours a day until the splint can maintain the range of motion.
The ankle splint can prevent the limitation of the ankle’s range of motion when the ankle is at a plantar grade position (2B). The recommended duration of use for ankle splint is 6–10 hours at night for 2–5 weeks.
While using non-custom-made splints, necessary precautions should be taken to prevent pressure sores (2B).
Performance improvement [41]:
The plantar spasticity ankle foot orthosis (AFO) can be used for better walking. In the case of mild spasticity, the single midline posterior stop AFO is used. The type of AFO with pins in the posterior channels can be used for more severe cases. Moreover, in patients with weak extensors of hip or knee, the solid type is recommended while the hinged type is suitable for patients with adequate control. In patients with crouched gait and passive range of motion in hip joints and pelvis, a ground reaction force AFO can be used.
Contracture improvement [40]:
It is possible to use casts at the end of range of motion for acute brain injury and stroke patients to improve the knee’s range of motion (2D). The cast should be replaced every 5–7 days. Use the cast for 2–12 weeks.
Short-term application of the cast (1–4 days) entails fewer complications compared to the longer uses (5–7 days) (2C).
Contracture prevention [40]:
Using casts at the end of range of motion in acute brain injury and stroke patients can prevent contractures (2C). The cast should be replaced every 5–7 days. Use the cast for a 2- to 5-week period.
Use this cast with caution in the patients with acute lesions (acute brain injury and stroke) and decreased level of consciousness for preventing secondary complications such as pressure sores (2C).
Knee splints can be used for standing control and walking improvement as well.
Contracture improvement [2, 40]:
Using splints for deformity correction in hand and wrists is not routinely advised for every patient (e.g., in stroke and acute brain injury patients). However, they can be used in certain cases in an optional way (2B). These splints are custom-made or serial and adjustable (10 degrees wrist extension and finger extension with MCP flexion, wrist at neutral, or maximal available range of movement). Most of them are used for 20 minutes to 12 hours a day for a 1- to 8-week period.
Contracture prevention [2, 40]:
Using splints for deformity prevention in hand and wrists is not routinely advised for every patient (e.g., in stroke and acute brain injury patients). However, they can be used in certain cases in an optional way (2B). In the studies, the splints have been used in different positions (10 degrees wrist extension and fingers fully extended, wrist at neutral, or close to maximal available range of movement) with duration of 6–12 hours a day for a 1- to 8-week period.
Using splints in combination with botulinum toxin in selected cases can be effective in reducing the spasticity that has resulted in range of motion loss (2C). The splint is used at the end of the available range of movement but is not adjusted daily. On the other hand, strapping is used at the end of available range of movement, with daily adjustment to maximal stretch for 6 days.
Using electrical stimulation in combination with splints is not recommended for contracture prevention (2A).
Custom-made hand and wrist splints should not be used routinely for prevention from spasticity exacerbation in acute brain injury and stroke patients (2B).
A wrist splint at neutral position can be effective in hand pain prevention caused by joint malalignment (2A). These splints should be used for minimum 6 hours a day for 13 weeks.
Performance improvement [2, 42]:
Sometimes, a splint is also used to improve performance (Figure 2) or prevent tissue damage (e.g., sheepskin palm protector).
Using volar splints in children with cerebral palsy can reduce the spasticity and improve the range of motion and performance in upper limb. However, theses splints are not effective on the upper limb movements in stroke patients.
Using dorsal splints has no effect on spasticity, range of motion, and performance of upper limb in stroke patients.
Dynamic splints can improve the upper limb performance and accelerate spasticity reduction.
The use of C-Bar splint is an effective method to improve hand performance and range of motion while decreasing spasticity in upper limb of cerebral palsy children.
Using anti-pronation splints can be an effective technique to improve the performance of upper limb, range of motion of forearm supination, and wrist extension, as well as reducing the severity of spasticity in forearms pronator muscles and wrist flexor muscles. These splints are also effective in improving the gripping and pinching ability in children suffering from spastic diplegia cerebral palsy.
Extension splints are not helpful in the rehabilitation program of stroke patients.
As a modern splint, SAEBO splints can be helpful in improving the upper limb of stroke patients.
In general, volar, dorsal, anti-pronation, and C-Bar splints are effective in spasticity reduction and performance improvement of upper limb in children with cerebral palsy while SAEBO and dynamic splints are useful for performance improvement and spasticity reduction of upper limb.
sheepskin palm protector is used to prevent tissue damage.
Contracture improvement [40, 42]:
Using casts is recommended at the end of range of motion to modify the elbow’s range of motion (2C). The cast should be replaced every 3–7 days. Use the cast for a 1- to 4-week period.
Short-term application of the cast (1–4 days) entails fewer complications compared to the longer use (4–7 days) (2C).
Enough studies for contracture correction by splint are not available.
Contracture prevention [40]:
Enough studies for contracture correction by splints are not available.
Performance improvement [42]:
Elbow gaiters are recommended to maintain extension and improve function.
Spinal braces are usually used in cases with muscle weakness. In the patients with spasticity being the predominant complaint, spinal braces are not frequently used. It is because they are difficult to fit on the patients, are not comfortable, and can induce breathing problems and sores [2]. In these cases, the use of customized seating with individualized truncal and pelvic support can be a more beneficial and comfortable option. The braces can be used in patients with kyphosis and scoliosis if it helps in sitting.
On the decision for the treatment of spasticity, considering goals is a critical point and pharmacological interventions should be considered with non-pharmacological treatment for optimizing the effectiveness of management [2]. Another important point in prescription of drugs is about the patient’s situation and the dosage and timing should be considered according to it. For example, painful nocturnal spasms may best be managed with a long-acting agent taken at night-time that has sedative side effects. As a rule for all medication, “start low and go slow” [2]. Although it is time-consuming, this approach will limit any deleterious effects on function or unwanted side effects. For better discussion, pharmacological interventions are categorized according to spasticity pattern including, generalized, segmental, and focal.
There are several oral treatments for management of generalized spasticity. However, there is more interest for some medications according to the country strategy (e.g., there is more discussion in American papers for Clonidine, but it is currently little used in the UK) [39]. Generally, these drugs are used more for spasticity management: baclofen, diazepam, tizanidine, dantrolene, gabapentin, and clonidine (Table 7). They may be used to provide systemic effect for modest spasticity severity. Choosing the drug is dependent on patient problems and goals [2, 39]. For example, if the neuropathic pain is a problematic as well as spasticity, gabapentin should be considered for this patient. Besides, some of the drugs are more recommended in papers for specific diagnosis; for example, gabapentin is also recommended as first- or second-line treatment for spasticity in the UK National Guidelines for Multiple Sclerosis [39].
Drug | Starting dose | Maximum dose | Side effects |
---|---|---|---|
Baclofen | 5–10 mg daily | 120 mg daily, usually in three divided doses | Drowsiness, weakness, paresthesia, nausea, vomiting |
Diazepam | 2 mg daily | 40–60 mg daily, usually in three or four divided doses | Drowsiness, reduced attention, memory impairment Dependency and withdrawal syndromes |
Tizanidine | 2 mg daily | 36 mg daily, usually in three or four divided doses | Drowsiness, weakness, dry mouth, postural hypotension Monitor liver function |
Dantrolene | 25 mg daily | 400 mg daily, usually in four divided doses | Anorexia, nausea, vomiting, drowsiness, weakness, dizziness, paraesthesiae Monitor liver function |
Gabapentin | 300 mg daily (can start at 100 mg daily) | 2400 mg daily, usually in three divided doses | Drowsiness, somnolence, dizziness |
Drugs in spasticity treatment.
There is no evidence-based consensus for combination drug regimes for oral treatment. However, they can be used according to associated features [2, 43]. There is no right or wrong way to titrate drugs in combination, and professionals suggest avoiding polypharmacy. If there is intolerance for maximum dose of first-line drug, continue the highest level the individual can tolerate comfortably and added the second-line drug and titrated upward. If the patient’s problem has been decreased with this regime, the first drug can be cautiously withdrawn to see if monotherapy with the second-line drug alone is sufficient to achieve the goal of treatment. For optimizing the treatment, it is very important the patient has had written information about treatment goals and efficacy and side effects of drugs.
Evidence-based recommendations for choosing the drug are listed below:
Baclofen: It is more effective in patients with either multiple sclerosis (MS) [44] or spinal cord injury and few have concentrated on spasticity of cerebral origin, including stroke or traumatic brain injury [43].
Tizanidine: It reduces sign and symptoms in MS, spinal cord injury and stroke; no functional benefit has, however, been demonstrated in MS and spinal cord injury [45].
Dantrolene: It is the only available agent that works out of CNS with direct action on skeletal muscle. So, it can be prescribed for spasticity originating from both spinal and supraspinal lesions. It is effective in management of MS patient and has modest effect in spinal cord injury, stroke, and cerebral palsy [46, 47, 48]. It does not demonstrate any changes in function.
Diazepam: The efficacy of it in spinal cord injury, cerebral palsy, and MS has been proven. However, its side effects are more than those of other drugs in the studies [43].
Gabapentin: There is beneficial effect of gabapentin on measures of spasticity in MS and spinal cord injury [49, 50].
Clonidine: Its major use has been as an anti-hypertensive agent, but it is efficient in the spinal cord injury spasticity [43].
In children’s spasticity, baclofen (for long treatment) and diazepam (for rapid onset) are recommended by NICE guideline [27].
This type of spasticity benefits from interathecal administration. This route of administration delivers the medication directly to where it is needed with less unwanted side effects like drowsiness and impaired cognition. Interathecal baclofen pump has been used since 30 years ago [39]. It is effective for lower limbs and trunk spasticity [51]. To manage changing needs, the dose and timing of drug delivery can be programmed over the 24-hour period. It has the beneficial effect in the autonomic storming in people with brain and spinal cord injury [39]. The risk of infection and the need to attend clinics every 3 months or so to have the pump refilled are its significant disadvantages.
The pump is recommended in children with severe motor function impairment (GMFCS level 3, 4, and 5) and bilateral spasticity affecting upper and lower limbs [27].
An intrathecal baclofen test to assess the therapeutic effect and adverse events is necessary before making the decision for intrathecal pump implantation. For evaluation of response, assessing the patient is necessary within 3–5 hours after sedation and recovery. Before pump implantation, written information is necessary including possible adverse effects, signs and symptoms suggesting the dose is too low or high, complications and follow-up appointments [27].
Implantation of the infusion pump can occur within 3 months of satisfactory response to intrathecal baclofen test [39].
Using intrathecal phenol injections is suggested in some studies too [52]. Compared with the intrathecal phenol, baclofen pump has complication of surgical procedure for implantation of pump, malfunction of pump, needing for dose adjustment and refilling the pump [52]. The advantages of intrathecal phenol include: less individual responsibility, low cost, no requirement of special equipment, and avoiding the regular clinical visits for refills. But the complications of this procedure are bladder and bowel incontinence, limb weakness, and paraesthesia, which are the reasons for intrathecal phenol not being considered for spasticity management routinely [52].
The most famous treatments that are used in this category are phenol neurolysis and botulinum toxin.
Phenol nerve block has been used for the treatment of spasticity since the 1960s and it has advantages in comparison with botulinum toxin including: faster onset of spasticity relief and greater degree of muscle relaxation for much longer and at much less expense [27, 39]. But it has disadvantages including, neurogenic pain or paraesthesia (if applied to a mixed motor/sensory nerve) and careful localization (needing for experienced hand), so some specialist prefer Botulinum toxin. However, it is appropriate for patients with troublesome spasticity and dystonia of hip adductors and calf muscles, especially for non-ambulant patients or “walkers” who are already dependent on an ankle-foot orthosis (AFO) [27, 39].
Botulinum toxin use has shown significant effects on improving the symptoms of patients with focal spasticity or dystonia [27, 39, 43]. The method of use and injection is discussed in detail in chapter x. Here is a brief explanation of its indications and contraindications.
There is more interest in botulinum toxin injection. This procedure for patients with focal spasticity in upper limb should be considered in the following cases [27]:
Impeding fine motor function
Compromising care and hygiene
Causing pain
Impeding tolerance of other treatments, such as orthoses
Causing cosmetic concern to the child and young person
Botulinum toxin injection for patients with focal spasticity in lower limb should be considered in the following cases [27]:
Impeding gross motor function
Compromising care and hygiene
Causing pain
Disturbing sleep
Impeding tolerance of other treatments, such as orthoses and use of equipment to support posture
Causing cosmetic concern to the child and young person
Botulinum toxin is not recommended in the following cases [27]:
Has severe muscle weakness
Had previous adverse reaction or allergy to the botulinum toxin type A
Is receiving aminoglycoside treatment
Administration of botulinum toxin should be done with caution in the following cases [27]:
The person has any of the following:
Bleeding disorders for example due to anticoagulant therapy
Generalized spasticity
Fixed muscle contracture
Marked bone deformity
There are concerns about people likelihood of engaging in post treatment adapted physical therapy treatment.
Setting up a spasticity clinic or service depends on the local conditions and available resources. Setting up a clinic needs a team in which every member has certain tasks. Undoubtedly, the roles and duties will overlap, but it is important to understand the abilities and skills of each professional to evaluate what they can offer for the treatment process [2]. Thus, outlining the key skills and roles of each team member and providing a competency framework can help in making an efficient team.
In general, four professionals have roles in a spasticity clinic team including a physician (a pediatric or adult neurologist or a physical medicine and rehabilitation specialist), nurse, occupational therapist, and physiotherapist [2]. In the following, the tasks of each professional are briefly discussed.
Physician:
Understanding the underlying condition, prognosis, natural history, associated features, and possible complications. Identifying the abnormal features or unexpected changes that may be caused by a secondary cause.
Being experienced in neuromuscular history-taking and physical examination.
Being able to perform necessary interventions including administering oral medications, botulinum toxin injection, intrathecal drug, and splint.
Nurse:
Educating the patient and his/her caregivers to manage spasticity.
Managing cutaneous and visceral triggers.
Advising the patient on posture, moving, and handling.
Managing psychosocial issues and considering the impact of spasticity on employment and social activities of the patient and managing it.
Monitoring the patient’s and caregiver’s adaptations with the treatments and ensuring that they follow the protocols and guidelines properly.
Physiotherapist:
Identifying the potential for movement patterns and functional ability to be improved.
Identifying trigger factors of spasticity related to posture and movement.
Identifying muscle weakness underlying the spasticity.
Occupational therapist:
Assessing the patient for proper use of splints.
Assessing the patient for posture and siting especially in a wheelchair.
Assessing the impact of spasticity on the patient’s performance.
Evaluating the patient’s access to work, home, and community environments.
Permanent presences of other specialists in the team are not necessarily needed, but they can be helpful in the treatment process. These specialists include orthopedics, neurosurgeons, speech therapists, orthotists, social workers, continence advisors, and psychologists.
One of the valuable points in setting up such services is their growth and development to provide better services. This goal is achieved through data collection, organization, and extraction so that effective and useful proposals will be presented. The development of these services based on this information results in optimizing the services as much as possible and targeted funding for treating these patients.
Spasticity is one of the common symptoms in a wide range of neurological conditions and it needs a multidisciplinary approach for best management. This chapter provided an excellent paradigm to incorporate many of the key elements that are fundamental, including: assessment of the individual with spasticity, provision of education and promoting self-management, physical management of spasticity (physiotherapy or occupational therapy), orthoses, pharmacological intervention, and setting up a service.
The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in this chapter.
Demographic data and checklist for impact of the spasticity on the patient’s communications and interactions with the environment.
Patient’s name: | Date of birth: | Date: | Diagnosis: |
---|---|---|---|
Current medication | Please comment on dose, route, times, and any side effects experienced | ||
Other medication used in the past for spasticity: Why did they stop taking it (ineffective, not tolerated, other reason?) | |||
Primary difficulty: Is it attributed to spasticity: Yes/No | Severity rating out of 10 | ||
Other difficulties related to spasticity: | |||
Spasticity | Please comment on site and severity of spasticity | ||
Not needing to be assessed | |||
Clonus | Please comment whether spontaneous | ||
Not needing to be assessed | |||
Spasms | Please comment on which muscles, extensors or flexors, severity, pain, frequency, and duration | ||
Not needing to be assessed | |||
Pain | Please comment on presence, severity, and management. Indicate if pain has been getting worse, better, or remains the same | ||
Not needing to be assessed | |||
Sleep patterns | Please comment on disturbances, positions, and quality | ||
Bed mobility | Please comment on how much, type of mattress used | ||
Not needing to be assessed | |||
Bladder | Please comment on current management | ||
Not needing to be assessed | |||
Bowel | Please comment on current management | ||
Not needing to be assessed | |||
Skin | Please comment on the presence of pressure ulcers and the ability to relieve pressure, change position and sensation, and any aids used (Waterlow Tool) | ||
Not needing to be assessed | |||
Mobility | Please comment on outdoor, indoor, aids, speed, and distance | ||
Not needing to be assessed | |||
Toilet/bath/shower transfers | Please comment on ability and aids required. Indicate if this has been getting worse, better, or remains the same | ||
Not needing to be assessed | |||
Transfers | Please comment on car, bed, chair, level of independence and assistance required | ||
Not needing to be assessed | |||
Wheelchair | Please comment on posture, position, type, and make of chair and cushion | ||
Not needing to be assessed | |||
Previous therapy and nursing input | Please comment on physiotherapy, OT, seating assessments, and nursing advice. Ensure details of time, date, and location of treatment obtained, including names, addresses, and contact details | ||
Options discussed with patient | |||
Assessment by: | Signature: |
The outcome measures of spasticity
Name: | Data | |
---|---|---|
Goniometry to measure range of passive movement (Norkin and White 1985): | Resting angle Right/left | Full range available Right/left |
Hip flexion-extension | ||
Hip abduction-adduction | ||
Knee flexion-extension | ||
Ankle PF-DF | ||
Maximum distance between knees as measured during passive hip abduction (Hyman 2000): | Distance in mm: | |
Modified Ashworth scale (Bohannon and Smith,1987): | Right | Left |
Resistance to: hip and knee flexion in supine | ||
Resistance to: hip and knee extension in supine | ||
Resistance to: hip abduction in crook lying | ||
Resistance to: ankle dorsiflexion with knee extended | ||
Clonus and spasms score (self-report) (Smith 1994)* | ||
Clonus | ||
Spasms | ||
Pain intensity by visual analogue scale(VAS) | ||
Seating posture score (please record 0 = yes, 1 = no) | ||
Are the feet well positioned on the footplates? | ||
Are the knees apart? | ||
Are the hips well aligned? | ||
Is the trunk posture symmetrical? | ||
Total | ||
Record the frequency of falls over the last month(0 = No falls, 1 = two to three falls per week, 2 = five to six falls per week, 3 = daily falls, 4 = more than one fall per day) | ||
10-metre timed walk (Wade 1987) | ||
No. of steps | ||
Time | ||
Aid used | ||
Identify the main problem that is amenable to treatment: |
0 = absent; 1 = Provoked by painful stimuli only; 2 = Provoked by touch, light pressure and/or occasionally spontaneous (5/day and/or < 2night); 3 = Provoked by passive movements (during physical therapy or nursing care) and/or frequently spontaneous (>5 day and/or 2/night).
IntechOpen books are available online by accessing all published content on a chapter level.
",metaTitle:"Access policy",metaDescription:"IntechOpen books are available online by accessing all published content on a chapter level",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"All IntechOpen published chapters are available OPEN ACCESS can be read without the requirement for registration of any kind, immediately upon publication, without any barrier.
\\n\\nThe HTML version, as well as the PDF version of publications dated before 2012 that are accessible through a reader, are available to readers with no restriction.
\\n\\nThe full content of chapters can be read, copied and printed from the link location of the chapter and these actions are not limited or restricted in any way.
\\n\\nRegistration is requested only to download the PDF of the chapter. There are no subscription fees and there is no charge to user groups.
\\n\\nIntechOpen chapters are distributed under CC BY 3.0 licences allowing users to “copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship...” and there is no non-commercial restriction.
\\n\\nAuthors may post published works to any repository or website with no delay, and Authors and Editors of IntechOpen books have direct access to the PDF of the full book.
\\n\\nAll published content can be crawled for indexing. Full text and metadata may be accessed with instructions publicly posted.
\\n\\nAll IntechOpen books are indexed in CLOCKSS and preservation of access to published content is clearly indicated.
\\n\\nPolicy last updated: 2021-02-26
\\n"}]'},components:[{type:"htmlEditorComponent",content:"All IntechOpen published chapters are available OPEN ACCESS can be read without the requirement for registration of any kind, immediately upon publication, without any barrier.
\n\nThe HTML version, as well as the PDF version of publications dated before 2012 that are accessible through a reader, are available to readers with no restriction.
\n\nThe full content of chapters can be read, copied and printed from the link location of the chapter and these actions are not limited or restricted in any way.
\n\nRegistration is requested only to download the PDF of the chapter. There are no subscription fees and there is no charge to user groups.
\n\nIntechOpen chapters are distributed under CC BY 3.0 licences allowing users to “copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship...” and there is no non-commercial restriction.
\n\nAuthors may post published works to any repository or website with no delay, and Authors and Editors of IntechOpen books have direct access to the PDF of the full book.
\n\nAll published content can be crawled for indexing. Full text and metadata may be accessed with instructions publicly posted.
\n\nAll IntechOpen books are indexed in CLOCKSS and preservation of access to published content is clearly indicated.
\n\nPolicy last updated: 2021-02-26
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5774},{group:"region",caption:"Middle and South America",value:2,count:5239},{group:"region",caption:"Africa",value:3,count:1721},{group:"region",caption:"Asia",value:4,count:10411},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15810}],offset:12,limit:12,total:118377},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateEndThirdStepPublish"},books:[{type:"book",id:"10231",title:"Proton Therapy",subtitle:null,isOpenForSubmission:!0,hash:"f4a9009287953c8d1d89f0fa9b7597b0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10231.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10652",title:"Visual Object Tracking",subtitle:null,isOpenForSubmission:!0,hash:"96f3ee634a7ba49fa195e50475412af4",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10652.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10653",title:"Optimization Algorithms",subtitle:null,isOpenForSubmission:!0,hash:"753812dbb9a6f6b57645431063114f6c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10653.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10655",title:"Motion Planning",subtitle:null,isOpenForSubmission:!0,hash:"809b5e290cf2dade9e7e0a5ae0ef3df0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10655.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10657",title:"Service Robots",subtitle:null,isOpenForSubmission:!0,hash:"5f81b9eea6eb3f9af984031b7af35588",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10657.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10662",title:"Pedagogy",subtitle:null,isOpenForSubmission:!0,hash:"c858e1c6fb878d3b895acbacec624576",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10662.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10673",title:"The Psychology of Trust",subtitle:null,isOpenForSubmission:!0,hash:"1f6cac41fd145f718ac0866264499cc8",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10673.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10675",title:"Hydrostatics",subtitle:null,isOpenForSubmission:!0,hash:"c86c2fa9f835d4ad5e7efd8b01921866",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10675.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10677",title:"Topology",subtitle:null,isOpenForSubmission:!0,hash:"85eac84b173d785f989522397616124e",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10677.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10678",title:"Biostatistics",subtitle:null,isOpenForSubmission:!0,hash:"f63db439474a574454a66894db8b394c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10678.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10679",title:"Mass Production",subtitle:null,isOpenForSubmission:!0,hash:"2dae91102099b1a07be1a36a68852829",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10679.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10689",title:"Risk Management in Construction",subtitle:null,isOpenForSubmission:!0,hash:"e3805b3d2fceb9d33e1fa805687cd296",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10689.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:18},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:5},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:20},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:25},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:202},popularBooks:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5249},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editedByType:"Edited by",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editedByType:"Edited by",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editedByType:"Edited by",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9669",title:"Recent Advances in Rice Research",subtitle:null,isOpenForSubmission:!1,hash:"12b06cc73e89af1e104399321cc16a75",slug:"recent-advances-in-rice-research",bookSignature:"Mahmood-ur- Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9669.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"481",title:"Instrumental Chemistry",slug:"instrumental-chemistry",parent:{title:"Analytical Chemistry",slug:"chemistry-analytical-chemistry"},numberOfBooks:7,numberOfAuthorsAndEditors:160,numberOfWosCitations:246,numberOfCrossrefCitations:108,numberOfDimensionsCitations:301,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"instrumental-chemistry",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"6831",title:"Gas Chromatography",subtitle:"Derivatization, Sample Preparation, Application",isOpenForSubmission:!1,hash:"b9ef7d64ef66b65cb3245157db815577",slug:"gas-chromatography-derivatization-sample-preparation-application",bookSignature:"Peter Kusch",coverURL:"https://cdn.intechopen.com/books/images_new/6831.jpg",editedByType:"Edited by",editors:[{id:"254714",title:"Dr.",name:"Peter",middleName:null,surname:"Kusch",slug:"peter-kusch",fullName:"Peter Kusch"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7221",title:"Atomic-force Microscopy and Its Applications",subtitle:null,isOpenForSubmission:!1,hash:"2320402a229f880b0be7c73b247ebcf4",slug:"atomic-force-microscopy-and-its-applications",bookSignature:"Tomasz Tański, Marcin Staszuk and Bogusław Ziębowicz",coverURL:"https://cdn.intechopen.com/books/images_new/7221.jpg",editedByType:"Edited by",editors:[{id:"15700",title:"Prof.",name:"Tomasz Arkadiusz",middleName:null,surname:"Tański",slug:"tomasz-arkadiusz-tanski",fullName:"Tomasz Arkadiusz Tański"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6125",title:"Calorimetry",subtitle:"Design, Theory and Applications in Porous Solids",isOpenForSubmission:!1,hash:"7057998c2bd96e7ee749cccf401a0464",slug:"calorimetry-design-theory-and-applications-in-porous-solids",bookSignature:"Juan Carlos Moreno-Piraján",coverURL:"https://cdn.intechopen.com/books/images_new/6125.jpg",editedByType:"Edited by",editors:[{id:"14015",title:"Dr.",name:"Juan Carlos",middleName:null,surname:"Moreno Piraján",slug:"juan-carlos-moreno-pirajan",fullName:"Juan Carlos Moreno Piraján"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6379",title:"Calibration and Validation of Analytical Methods",subtitle:"A Sampling of Current Approaches",isOpenForSubmission:!1,hash:"b2accb70a1680c9d57a55484a1852a10",slug:"calibration-and-validation-of-analytical-methods-a-sampling-of-current-approaches",bookSignature:"Mark T. Stauffer",coverURL:"https://cdn.intechopen.com/books/images_new/6379.jpg",editedByType:"Edited by",editors:[{id:"97565",title:"Dr.",name:"Mark",middleName:"Thomas",surname:"Stauffer",slug:"mark-stauffer",fullName:"Mark Stauffer"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2327",title:"Chromatography",subtitle:"The Most Versatile Method of Chemical Analysis",isOpenForSubmission:!1,hash:"730549acc4ff27929bb106ba63661172",slug:"chromatography-the-most-versatile-method-of-chemical-analysis",bookSignature:"Leonardo de Azevedo Calderon",coverURL:"https://cdn.intechopen.com/books/images_new/2327.jpg",editedByType:"Edited by",editors:[{id:"177382",title:"Dr.",name:"Leonardo de Azevedo",middleName:null,surname:"Calderon",slug:"leonardo-de-azevedo-calderon",fullName:"Leonardo de Azevedo Calderon"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2114",title:"Advanced Gas Chromatography",subtitle:"Progress in Agricultural, Biomedical and Industrial Applications",isOpenForSubmission:!1,hash:"039ef2e529d905397d4775625fcc9ef5",slug:"advanced-gas-chromatography-progress-in-agricultural-biomedical-and-industrial-applications",bookSignature:"Mustafa Ali Mohd",coverURL:"https://cdn.intechopen.com/books/images_new/2114.jpg",editedByType:"Edited by",editors:[{id:"108777",title:"Dr.",name:"Mustafa",middleName:null,surname:"Ali Mohd",slug:"mustafa-ali-mohd",fullName:"Mustafa Ali Mohd"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2248",title:"Applications of Gas Chromatography",subtitle:null,isOpenForSubmission:!1,hash:"a085440aee8d8c2c09b577246ede87ad",slug:"applications-of-gas-chromatography",bookSignature:"Reza Davarnejad and Mahboubeh Jafarkhani",coverURL:"https://cdn.intechopen.com/books/images_new/2248.jpg",editedByType:"Edited by",editors:[{id:"88069",title:"Dr.",name:"Reza",middleName:null,surname:"Davarnejad",slug:"reza-davarnejad",fullName:"Reza Davarnejad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:7,mostCitedChapters:[{id:"32817",doi:"10.5772/33098",title:"Derivatization Reactions and Reagents for Gas Chromatography Analysis",slug:"derivatization-reactions-and-reagents-for-gas-chromatography-analysis",totalDownloads:69805,totalCrossrefCites:27,totalDimensionsCites:80,book:{slug:"advanced-gas-chromatography-progress-in-agricultural-biomedical-and-industrial-applications",title:"Advanced Gas Chromatography",fullTitle:"Advanced Gas Chromatography - Progress in Agricultural, Biomedical and Industrial Applications"},signatures:"Francis Orata",authors:[{id:"94007",title:"Dr.",name:"Francis",middleName:null,surname:"Orata",slug:"francis-orata",fullName:"Francis Orata"}]},{id:"40383",doi:"10.5772/51676",title:"Analytical Methods for Quantification of Drug Metabolites in Biological Samples",slug:"analytical-methods-for-quantification-of-drug-metabolites-in-biological-samples",totalDownloads:10505,totalCrossrefCites:9,totalDimensionsCites:15,book:{slug:"chromatography-the-most-versatile-method-of-chemical-analysis",title:"Chromatography",fullTitle:"Chromatography - The Most Versatile Method of Chemical Analysis"},signatures:"Robert Roškar and Tina Trdan Lušin",authors:[{id:"144516",title:"MSc.",name:"Tina",middleName:null,surname:"Trdan Lušin",slug:"tina-trdan-lusin",fullName:"Tina Trdan Lušin"},{id:"148490",title:"Dr.",name:"Robert",middleName:null,surname:"Roškar",slug:"robert-roskar",fullName:"Robert Roškar"}]},{id:"32823",doi:"10.5772/33488",title:"GC Analysis of Volatiles and Other Products from Biomass Torrefaction Process",slug:"gc-analysis-of-volatiles-and-other-products-from-biomass-torrefaction-process",totalDownloads:15507,totalCrossrefCites:1,totalDimensionsCites:15,book:{slug:"advanced-gas-chromatography-progress-in-agricultural-biomedical-and-industrial-applications",title:"Advanced Gas Chromatography",fullTitle:"Advanced Gas Chromatography - Progress in Agricultural, Biomedical and Industrial Applications"},signatures:"Jaya Shankar Tumuluru, Shahab Sokhansanj, Christopher T. Wright and Timothy Kremer",authors:[{id:"95803",title:"Dr.",name:"Jaya Shankar",middleName:null,surname:"Tumuluru",slug:"jaya-shankar-tumuluru",fullName:"Jaya Shankar Tumuluru"},{id:"95806",title:"Dr.",name:"Sokhansanj",middleName:null,surname:"Shahab",slug:"sokhansanj-shahab",fullName:"Sokhansanj Shahab"},{id:"130245",title:"Dr.",name:"Timothy G",middleName:null,surname:"Kremer",slug:"timothy-g-kremer",fullName:"Timothy G Kremer"},{id:"135381",title:"Dr.",name:"Christopher T.",middleName:null,surname:"Wright",slug:"christopher-t.-wright",fullName:"Christopher T. Wright"}]}],mostDownloadedChaptersLast30Days:[{id:"57909",title:"Validation of Analytical Methods",slug:"validation-of-analytical-methods",totalDownloads:4111,totalCrossrefCites:5,totalDimensionsCites:7,book:{slug:"calibration-and-validation-of-analytical-methods-a-sampling-of-current-approaches",title:"Calibration and Validation of Analytical Methods",fullTitle:"Calibration and Validation of Analytical Methods - A Sampling of Current Approaches"},signatures:"Tentu Nageswara Rao",authors:[{id:"220824",title:"Dr.",name:"Tentu",middleName:null,surname:"Nageswara Rao",slug:"tentu-nageswara-rao",fullName:"Tentu Nageswara Rao"}]},{id:"58596",title:"Linearity of Calibration Curves for Analytical Methods: A Review of Criteria for Assessment of Method Reliability",slug:"linearity-of-calibration-curves-for-analytical-methods-a-review-of-criteria-for-assessment-of-method",totalDownloads:5049,totalCrossrefCites:5,totalDimensionsCites:12,book:{slug:"calibration-and-validation-of-analytical-methods-a-sampling-of-current-approaches",title:"Calibration and Validation of Analytical Methods",fullTitle:"Calibration and Validation of Analytical Methods - A Sampling of Current Approaches"},signatures:"Seyed Mojtaba Moosavi and Sussan Ghassabian",authors:[{id:"216099",title:"Dr.",name:"Sussan",middleName:null,surname:"Ghassabian",slug:"sussan-ghassabian",fullName:"Sussan Ghassabian"},{id:"216101",title:"Mr.",name:"Seyed Mojtaba",middleName:null,surname:"Moosavi",slug:"seyed-mojtaba-moosavi",fullName:"Seyed Mojtaba Moosavi"}]},{id:"64643",title:"Derivatization Methods in GC and GC/MS",slug:"derivatization-methods-in-gc-and-gc-ms",totalDownloads:4089,totalCrossrefCites:7,totalDimensionsCites:11,book:{slug:"gas-chromatography-derivatization-sample-preparation-application",title:"Gas Chromatography",fullTitle:"Gas Chromatography - Derivatization, Sample Preparation, Application"},signatures:"Serban C. Moldoveanu and Victor David",authors:[{id:"91597",title:"Dr.",name:"Serban",middleName:null,surname:"Moldoveanu",slug:"serban-moldoveanu",fullName:"Serban Moldoveanu"},{id:"278733",title:"Prof.",name:"Victor",middleName:null,surname:"David",slug:"victor-david",fullName:"Victor David"}]},{id:"66518",title:"Sample Preparation Techniques for Gas Chromatography",slug:"sample-preparation-techniques-for-gas-chromatography",totalDownloads:3235,totalCrossrefCites:1,totalDimensionsCites:3,book:{slug:"gas-chromatography-derivatization-sample-preparation-application",title:"Gas Chromatography",fullTitle:"Gas Chromatography - Derivatization, Sample Preparation, Application"},signatures:"Foujan Falaki",authors:[{id:"269763",title:"Dr.",name:"Foujan",middleName:null,surname:"Falaki",slug:"foujan-falaki",fullName:"Foujan Falaki"}]},{id:"40383",title:"Analytical Methods for Quantification of Drug Metabolites in Biological Samples",slug:"analytical-methods-for-quantification-of-drug-metabolites-in-biological-samples",totalDownloads:10506,totalCrossrefCites:9,totalDimensionsCites:15,book:{slug:"chromatography-the-most-versatile-method-of-chemical-analysis",title:"Chromatography",fullTitle:"Chromatography - The Most Versatile Method of Chemical Analysis"},signatures:"Robert Roškar and Tina Trdan Lušin",authors:[{id:"144516",title:"MSc.",name:"Tina",middleName:null,surname:"Trdan Lušin",slug:"tina-trdan-lusin",fullName:"Tina Trdan Lušin"},{id:"148490",title:"Dr.",name:"Robert",middleName:null,surname:"Roškar",slug:"robert-roskar",fullName:"Robert Roškar"}]},{id:"32817",title:"Derivatization Reactions and Reagents for Gas Chromatography Analysis",slug:"derivatization-reactions-and-reagents-for-gas-chromatography-analysis",totalDownloads:69807,totalCrossrefCites:27,totalDimensionsCites:80,book:{slug:"advanced-gas-chromatography-progress-in-agricultural-biomedical-and-industrial-applications",title:"Advanced Gas Chromatography",fullTitle:"Advanced Gas Chromatography - Progress in Agricultural, Biomedical and Industrial Applications"},signatures:"Francis Orata",authors:[{id:"94007",title:"Dr.",name:"Francis",middleName:null,surname:"Orata",slug:"francis-orata",fullName:"Francis Orata"}]},{id:"40405",title:"Current Trends in Sample Treatment Techniques for Environmental and Food Analysis",slug:"current-trends-in-sample-treatment-techniques-for-environmental-and-food-analysis",totalDownloads:4426,totalCrossrefCites:1,totalDimensionsCites:10,book:{slug:"chromatography-the-most-versatile-method-of-chemical-analysis",title:"Chromatography",fullTitle:"Chromatography - The Most Versatile Method of Chemical Analysis"},signatures:"Paolo Lucci, Deborah Pacetti, Oscar Núñez and Natale G. Frega",authors:[{id:"87645",title:"Prof.",name:"Natale G.",middleName:null,surname:"Frega",slug:"natale-g.-frega",fullName:"Natale G. Frega"},{id:"92665",title:"Dr.",name:"Deborah",middleName:null,surname:"Pacetti",slug:"deborah-pacetti",fullName:"Deborah Pacetti"},{id:"142852",title:"Dr.",name:"Paolo",middleName:null,surname:"Lucci",slug:"paolo-lucci",fullName:"Paolo Lucci"},{id:"151384",title:"Dr.",name:"Oscar",middleName:null,surname:"Núñez",slug:"oscar-nunez",fullName:"Oscar Núñez"}]},{id:"40373",title:"Instrumental Analysis of Tetrodotoxin",slug:"instrumental-analysis-of-tetrodotoxin",totalDownloads:3373,totalCrossrefCites:1,totalDimensionsCites:8,book:{slug:"chromatography-the-most-versatile-method-of-chemical-analysis",title:"Chromatography",fullTitle:"Chromatography - The Most Versatile Method of Chemical Analysis"},signatures:"Manabu Asakawa, Yasuo Shida, Keisuke Miyazawa and Tamao Noguchi",authors:[{id:"147465",title:"Prof.",name:"Manabu",middleName:null,surname:"Asakawa",slug:"manabu-asakawa",fullName:"Manabu Asakawa"},{id:"148365",title:"Dr.",name:"Yasuo",middleName:null,surname:"Shida",slug:"yasuo-shida",fullName:"Yasuo Shida"},{id:"156220",title:"Prof.",name:"Keisuke",middleName:null,surname:"Miyazawa",slug:"keisuke-miyazawa",fullName:"Keisuke Miyazawa"},{id:"156221",title:"Prof.",name:"Tamao",middleName:null,surname:"Noguchi",slug:"tamao-noguchi",fullName:"Tamao Noguchi"}]},{id:"40376",title:"Using High Performance Liquid Chromatography (HPLC) for Analyzing Feed Additives",slug:"using-high-performance-liquid-chromatography-hplc-for-analyzing-feed-additives",totalDownloads:19416,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"chromatography-the-most-versatile-method-of-chemical-analysis",title:"Chromatography",fullTitle:"Chromatography - The Most Versatile Method of Chemical Analysis"},signatures:"Jolanta Rubaj, Waldemar Korol and Grażyna Bielecka",authors:[{id:"146979",title:"Dr.",name:"Jolanta",middleName:null,surname:"Rubaj",slug:"jolanta-rubaj",fullName:"Jolanta Rubaj"}]},{id:"40379",title:"Analysis of Surfactants in Environmental Samples by Chromatographic Techniques",slug:"analysis-of-surfactants-in-environmental-samples-by-chromatographic-techniques",totalDownloads:9033,totalCrossrefCites:0,totalDimensionsCites:3,book:{slug:"chromatography-the-most-versatile-method-of-chemical-analysis",title:"Chromatography",fullTitle:"Chromatography - The Most Versatile Method of Chemical Analysis"},signatures:"Juan M. Traverso-Soto, Eduardo González-Mazo and Pablo A. Lara-Martín",authors:[{id:"144611",title:"Dr.",name:"Pablo Antonio",middleName:null,surname:"Lara-Martín",slug:"pablo-antonio-lara-martin",fullName:"Pablo Antonio Lara-Martín"},{id:"144615",title:"MSc.",name:"Juan Manuel",middleName:null,surname:"Traverso-Soto",slug:"juan-manuel-traverso-soto",fullName:"Juan Manuel Traverso-Soto"},{id:"144616",title:"Dr.",name:"Eduardo",middleName:null,surname:"González-Mazo",slug:"eduardo-gonzalez-mazo",fullName:"Eduardo González-Mazo"}]}],onlineFirstChaptersFilter:{topicSlug:"instrumental-chemistry",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/176237/qingrui-zhang",hash:"",query:{},params:{id:"176237",slug:"qingrui-zhang"},fullPath:"/profiles/176237/qingrui-zhang",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()